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    INTRODUCTION 
 Oral cancer is a malignant neoplasm which occurs in the lip, floor of 
the mouth, cheek lining, gingiva, palate, maxillary and mandibular alveolar 
process or in the tongue.  Worldwide oral carcinomas is one of the most 
prevalent cancer and is one of the ten most common causes of death.
23
 In India 
oral cancer is one among the top three cancers among which 90% - 95% are 
squamous cell carcinomas. They arise specifically in the squamous epithelium 
of the various regions in the oral cavity.  Severe alcoholism, use of tobacco in 
any form (smokeless/ those that liberate smoke), poor oral hygiene, oncogenic 
viruses, especially human papilloma virus and poor dietary habits are directly 
attributed to the occurrence of oral cancer. The International  Agency for 
Research on Cancer has predicted that in India the incidence of cancer will 
increase from 1 million in 2012 to more than 1,7 million in 2035.
61
    
           Since oral cancer remains a major health problem and the incidence is 
bound to increase by 2030 in both the sexes, early detection, prompt treatment 
and prevention will reduce the burden in future. The principal objective of 
treatment is to cure the patient of cancer. The choice of treatment is primarily 
determined by the cell type, degree of differentiation, size, location and 
aggressiveness of the primary tumour, extent of nodal involvement and the 
estimated functional impact of therapy.
37 
          Aggressive multimodality treatment with curative intent may include 
surgery, radiotherapy and chemotherapy. Either surgery or radiation may be 
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used for many T1 and T2 lesions, however surgery is specifically indicated for 
tumours involving bone , for recurrent tumours and for tumours that lack 
sensitivity to radiation.
23 
            Radiotherapy may be used alone or as a part of multimodality 
approach, and often with significant short and long term side effects. In radical 
radiotherapy though the is intention is to cure the patient, the total dose is 
high, the course of therapy is prolonged and the early and late radiation effects 
are common. In palliative care, radiation may provide symptomatic relief from 
pain, bleeding, ulceration, and oropharyngeal obstruction.
23 
         There are various means by which radiation is delivered, the most 
common being brachytherapy and external beam radiotherapy. In 
brachytherapy interstitial and intercavitary implants may be used for treating 
localized tumours in the anterior two thirds of the oral cavity and for boosted 
doses of radiation to a specific site
23
.   The cobalt units have been used for 
traditional teletherapy equipments and they produce stable dichromatic beams 
of 1.17 and 1.33 MeV, resulting in an average beam energy of 1.25 MeV. The 
role of cobalt has been increasingly replaced by the linear accelerator, which 
can generate higher energy of electrons in the energy range of 4, 6, 15 and 18 
MeV.
37 
          Radiation therapy designs have evolved over the past 30 years from 
being based on two dimensional (2D) to three dimensional images, 
incorporating increasingly complex computer algorithms. The shape and 
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intensity of the electron beam has to be collimated to attain the highest 
probability of tumour control or cure with the least amount of morbidity and 
toxicity to normal surrounding tissues (sometimes referred to as organs at 
risk).
28 
           In three dimensional conformal radiotherapy the radiation conforms 
to the shape of the volume  to be treated and is most useful for tumours that 
are close to important structures like prostrate, spine, oesophagus, lung, 
bladder, pancreas, head and neck etc. The primary advantage of this imaging 
modality is dose escalation within the target volume that theoretically should 
increase the therapeutic ratio.
18
 In Intensity modulated radiotherapy the 
physician designates specific doses of radiation (constraints) that the tumour 
and normal surrounding tissues receive and then uses a computer programme 
to develop an individualized plan to meet the constraints, called inverse 
treatment planning.
25
 In image guided radiotherapy the  linear accelerator is 
equipped with an imaging technology that allows the physician to image the 
tumour immediately before or even during the time the radiation is delivered, 
while the patient is positioned on the treatment table.
35 
             In stereotactic body radiotherapy, the tumour location can be tracked 
in four dimensions (including time) using several CT imaging techniques that 
depend on the platform, tracking on bony structures or implanted fiducials. In 
proton therapy, high energy, positively charged particles, are used, which 
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enables physicians to deliver high energy conformal doses to the tumour 
volume while almost completely sparing normal tissues.
44 
             Though radiation delivery methods and beam shaping has evolved 
continuously with novel methods, it is not without some pitfalls, the most 
important being acute and chronic toxicities that develop after radiotherapy. 
Toxicities that develop within 90 days from the beginning of radiotherapy are 
acute and that developing after 90 days is chronic. The most common acute 
side effects are mucositis, skin reactions, dysphagia and dysguesia. The 
chronic toxicities that develop include xerostomia, and difficulty in mouth 
opening due to fibrosis. Thus acute and late toxicities of radiotherapy in cancer 
patients represent important clinical outcomes that can substantially reduce 
quality of life and the ability of individuals to complete the entire planned 
course of treatment.  
            The purpose of the present study is to explore the  acute and chronic 
toxicity profiles associated 3DCRT, IMRT and IGRT in oral cancer patients  
which would help us to further optimize the process and incorporate re 
planning strategies to obtain an even better locoregional control and thus 
produce a potential positive impact on the quality of life of the patient. 
   
                                                                           Aims & Objectives 
 
5 
 
               AIMS AND OBJECTIVES 
AIM OF THE STUDY: 
 To compare and assess the acute and chronic toxicity profiles of head 
and neck cancer patients undergoing radiotherapy by 3D CRT, IMRT and 
IGRT modes of treatment. 
OBJECTIVE OF THE STUDY: 
1. To evaluate the toxicity profiles in patients undergoing 3D CRT. 
2. To evaluate the toxicity profiles in patients undergoing IMRT. 
3. To evaluate the toxicity profiles in patients undergoing IGRT. 
4. To compare and assess the toxicity profiles among 3D CRT, IMRT and 
IGRT patients. 
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                                            REVIEW OF LITERATURE 
 
 Worldwide, oral carcinoma is one of the most common cancers and 
one of the ten most prevalent causes of death and the majority of cancers are 
squamous cell cancers. Other malignant diseases that can occur in the head  
and neck include tumours of the salivary gland, thyroid gland, lymph nodes 
and soft tissues.  
             Approximately 95% of oral squamous cell carcinomas occurs between 
25 – 40 years. The majority of oral cancers involve the tongue, oropharynx, 
and floor of the mouth. The lips, gingival, dorsal tongue and palate are less 
common sites. African Americans in theUnited States have a higher risk of  
developing oropharyngeal cancer than do Caucasians. The increased risk 
appears to be due to environmental factors, although possible genetic 
factors have not been determined.
23 
EPIDEMIOLOGY OF ORAL CANCER IN INDIA: 
 Ken Russell Coelho ( 2012)
33
  has put forth a review article which 
provides a synopsis of the incidence of oral cancer in India by focussing on 
it’s measurement in cancer registries across the country. This paper discusses 
about the high burden of oral cancer in India, case definition of oral cancer, 
the systematic  search  strategy  about the literature on oral cancer along with 
the results, measurement of  incidence of oral cancer, about the cancer registry 
data and comparisons with the IARC sources, trends in oral cancer in India, 
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variability in incidence, aetiological factors, tobacco usage, global burden of 
disease, limitations , projections, screening and early detection and future 
challenges. 
HIGH BURDEN OF ORAL CANCER IN INDIA:  
        Oral cancer is a major problem in the Indian subcontinent.  It ranks 
among the top three types of cancer in the country with  the incidence being  
20 per 100,000 population and accounts for over 30% of all cancers in the 
country the main cause being  the combined effect of ageing of the population, 
as well as regional differences in the prevalence of disease-specific risk 
factors. 
CASE DEFINITION OF ORAL CANCER: 
          Oral cancer is defined as cancer of, mouth, tongue and lip to include the 
anatomic description of the oral cavity as reported in previous major 
population based research reports.    Based on these criteria, oral cavity cancer 
is the 8th most frequent cancer in the world among males and 14th among 
females , the main risk factors being tobacco and alcohol use. 
SEARCH STRATEGY:  
          A systematic search of the literature was accomplished using the 
Pubmed Database. Medical Subject headings and free  text terms included the 
following: 
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1. “Oral Cancer” OR “Lip Cancer” OR “ Tongue Cancer”. 
2. “Epidemiology” OR “Descriptive Statistics” OR “Incidence” OR 
“Prevalence” OR “Longitudinal” OR “Cohort” OR “Case Control” OR 
“Cross sectional.” 
Free text terms included, 
     3. India OR South Asia 
SUMMARY OF THE FINDINGS:  
           Gupta et al.  conducted a case-control study; however, this study was 
nested within a larger study utilising a rural based population registry. 
Sankaranarayanan et al  utilised a community based cluster-randomised 
controlled trial where participants were randomised to either an intervention 
group or a control group to test the effect of a screening programme on the 
oral cancer incidence and mortality. Mehta et al.  utilised a mixed methods 
approach conducted in different phases. Malaowalla et al.  Gupta et al and 
Cancela et al.  conducted population-based prospective cohort studies to 
examine the incidence of oral cancer tracked prospectively 
over a period of time. A number of survey methods were employed, including 
house-to-house recruitment, interviewing, and data abstraction from medical 
records. 
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MEASUREMENT OF DISEASE INCIDENCE: 
           An increasing trend based on age; however, lower incidence recorded 
amongst females as compared to males is indicative of gender differences in 
the lifestyle and behavioural patterns associated with incidence of oral cancer. 
Different studies reported a range of age-adjusted incidence rates (per 100,000 
population) for oral cancer.  
INCIDENCE AND TRENDS OF ORAL CANCER IN INDIA: 
         Oral cancer accounts for over 30% of all cancers in India. The variation 
in incidence and pattern of oral cancer is due to regional 
differences in the prevalence of risk factors. 
VARIABILITY IN INCIDENCE: 
         The incidence varies considerably based on study designs, 
sampling methodology and case ascertainment, as well as by 
age, gender and location. Variations in age-specific incidence 
rates also increased with age, which drops at the age of 
seventy, a trend which is consistent in multiple studies. 
AETIOLOGICAL FACTORS: 
             The use of tobacco (smoking or chewing) or alcohol intake is 
associated with oral cancer. Several studies discussed the associations between 
use of tobacco and oral cancer incidence.  Mehta et al.  reported the 
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regression rate of leukoplakia as significantly higher among those who had 
stopped or reduced tobacco consumption in rural populations in Kerala, 
Andhra Pradesh and Gujarat. Gupta et al reported an association between the 
cessation of tobacco habits and a drop in the incidence of leukoplakia 
implying reduced risk for oral cancer after cessation of tobacco use. 
Khandekar et al.  reported tobacco consumption habits among subjects that 
included chewing (in the form of betel quid, or khaini) and 
smoking (bidis and cigarettes) as the common cause of oral 
cancer. Based on the TNM classification, 48% of these oral 
cancer cases presented in later stages, that is, III and IV. 
TOBACCO USE:  
          57% of all men and 11% of women between 15–49 years of age use 
some form of tobacco which include the use of ghutks, mawa, zarra, khainni, 
pan etc. Recently, the trend has also been observed towards 
increased incidence of oral cancer among young adults. This 
increase in incidence is observed in patients with tongue 
cancer. 
GLOBAL BURDEN OF DISEASE:  
             Approximately 12% of deaths worldwide occur due to cancer, 
and in about twenty years, it is projected to increase from 
about 6 to 10 million. 
                                                                  Review of literature 
 
11 
 
LIMITATIONS: 
            A number of studies may not have been found using the 
identified search strategy. Secondly, mortality and survival 
from oral cancer in India have not been described. Finally, the search 
strategy was also limited to studies published in English, 
leaving out local language-based Indian journals. 
PROJECTIONS: 
          Oral cancer in particular will continue to be a major problem.  Crude 
incidence projections by Globocan demonstrate that oral cancer crude 
incidence will increase in India by 2020 and 2030 in both sexes. 
SCREENING AND EARLY DETECTION: 
             Early detection would not only improve the cure rate, but it would also 
lower the cost and morbidity associated with treatment. Mouth self-
examination could further reduce the cost of the screening and increase 
awareness in high-risk communities in India. Such a simple and cost-effective 
strategy has the potential to have a significant impact on the awareness of oral 
cancer in the broader community. 
FUTURE CHALLENGES:  
         There exists a significant gap in the Indian public’s knowledge, attitudes, 
and behaviours and efforts must be made to overcome this. Prevention through 
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action against risk factors, especially tobacco will be key to reducing the 
burden amongst these groups 
ETIOLOGY AND RISK FACTORS ASSOCIATED WITH  CANCER: 
      Murthy et al (2004)
44
 have reviewed on the various aetiological factors 
related to oral cancer: 
TOBACCO USAGE: 
          The principle impact of tobacco smoking is seen in higher incidence of 
cancers of the lung, larynx, oesophagus, pancreas and bladder. Bidi smoking is 
associated with cancer of oropharynx as well as larynx. This could be due to 
poor combustibility as well as the nicotine and tar content of bidi which 
exceeds that of cigarette.  
ALCOHOL CONSUMPTION: 
          Epidemiological studies carried out in India and abroad have shown that 
increased alcohol consumption is causally associated with cancers at various 
sites, mainly oral cavity, pharynx, larynx, and oesophagus.  A prospective 
study in India has found that alcohol consumption increases the incidence by 
49% among current users and 90% in past drinkers. This could be due to 
residual effect of alcohol consumption or them having quit the habit due to 
serious illness. Consumption of alcoholic beverages was associated with 
increased risk for Oral cancer in men but it was not observed in women 
because very few women consumed alcohol. 
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INFECTIONS: 
         There is strong evidence that majority of cervical neoplasia is caused by 
certain sub types of human papilloma virus (HPV), a sexually transmitted 
infection. Studies carried out in India have also confirmed the role of HPV 
and cervical cancer. Other virus–cancer relationships are between Epstein–
Barr virus and nasopharyngeal cancer; chronic active infection and hepatitis B 
virus and primary liver cancer; Helicobacter pylori and stomach cancer; HIV 
and Kaposi’s sarcoma and some forms of lymphoma. 
DIET AND CANCER: 
            Increased intake of fat and red meat associated with a higher risk of 
colorectal cancer and probably prostate cancer. High consumption of fruits and 
vegetables is associated with reduced risk of several cancers including lung, 
oral, pancreas, larynx, oesophagus, bladder, stomach and cervical cancers. 
 SEXUAL AND REPRODUCTIVE FACTORS: 
          Epidemiological data strongly implicate sexually transmitted agents in 
the aetiology of cervical cancer . Studies carried out have been shown that 
early onset of menarche, late age at first child birth, nulli-parity and late 
natural menopause increase the risk of breast cancer . Early age at first sexual 
intercourse and multiple sexual partners add to the risk of cancer of the cervix. 
Murthy et al ( 2004)
44
 has also focussed on the role of population based 
cancer registry (PCBR) as the source of data in estimating the incidence and 
                                                                  Review of literature 
 
14 
 
mortality rate  of cancer cases in a defined region. From the PCBR  the age  
adjusted incidence rates vary from 44 to 122   per 100,000 in males and 52 to 
128 per 100,000  in females. The population registries also suggest a variation 
in sitewise distribution among the various regions of India. 
 PATHOPHYSIOLOGY OF CANCER: 
            The molecular pathogenesis of OSCC reflects an accumulation of 
genetic changes that occur over a period of years. 20% of OSCCs are 
documented arising in or are associated with a clinically visible precursor 
lesion, such as leukoplakia and erythroplakia. Major genes involved 
in head and neck squamous cell carcinoma (HNSCC) include 
proto-oncogenes and tumor suppressor genes (TSGs). Other factors that play a 
role in the progression of disease may include allelic loss at other chromosome 
regions, mutations to proto-oncogenes and TSGs, or epigenetic changes such 
as deoxyribonucleic acid (DNA) methylation or histone deacetylation. 
Cytokine growth factors, angiogenesis, cell adhesion molecules, immune 
function, and homeostatic regulation of surrounding normal cells also play a 
role. Proto-oncogenes associated with HNSCC include ras (rat sarcoma), 
cyclin-D1, myc, erb-b (erythroblastosis), bcl-1, bcl-2 (B-cell lymphoma), 
int-2, CK8, and CK19.
23 
          Williams H. K. (2000)
63
 in his review of  the molecular pathogenesis of 
oral squamous carcinoma delivers details  about genetic alterations which 
could be point mutations, amplifications, rearrangements and deletions 
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Several oncogenes have also been implicated in oral carcinogenesis. Aberrant 
expressions of the proto – oncogenes epidermal growth factor receptor, 
members of the ras gene family, c – myc, int -2, PRAD – 1 and bcl – 1 is 
believed to contribute towards cancer development. With regards to tumour 
suppressor genes, mutation of the p53 gene, p21, and retinoblastoma gene 
results in progression of squamous cell carcinomas. 
            The author has finally discussed the role of  cell adhesion molecules in 
which there is a loss or reduced expression of beta 1 integrins and alpha 6 beta 
4, especially in poorly differentiated carcinomas. The association of viruses 
with cancer seems to be very important   with the fact that oral epithelial 
dysplasia which is a precursor to squamous carcinoma, is infected with HPV, 
and type 2, 6, 11, 18, 31, 33, 35 have been detected. Most of the oral 
squamous cell carcinomas are found to contain HPV – 16 and HPV – 18. 
These viruses contain gene products ( E6 and E7) that bind wild type p53 and 
Rb proteins and eliminate the ability of these proteins to stimulate DNA repair 
or apoptosis. 
PRESENTING SIGNS AND SYMPTOMS OF ORAL CANCER: 
           Discomfort is the most common  symptom ( 85% of patients ) that lead 
a patient to seek care. The patient is also aware of a mass in the mouth or neck. 
Dysphagia, odynophagia, otalgia, limited movement, oral bleeding and neck 
masses may occur in advanced cases. The patient should be assessed for  
tissue changes that include a red, white or red/ white lesion, a change in the 
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surface texture of the lesion producing a granular, smooth , crusted, lesion; or 
the presence of a mass or ulceration. The lymphatic spread of the carcinoma 
usually involves the  submandibular, digastrics , upper cervical nodes and 
finally the remaining lymph nodes of the  cervical chain. Lymph nodes 
associated with cancer become enlarged and firm to hard in texture. Accurate 
node examination is needed before biopsy, and the individual who is 
performing the procedure must be experienced in lymph node palpation.
23 
CLINICAL FEATURES OF ORAL SQUAMOUS CELL CARCINOMA: 
          Persons with OSCC are most often older men who have been aware of 
an alteration in an oral cancer site for 4 to 8 months before seeking 
professional help, the reason perhaps being that there is minimal pain during 
the early growth phase. It has a varies clinical presentations which include 
1. Exophytic ( mass forming; fungating, papillary, verruciform) 
2. Endophytic ( invasive, burrowing, ulcerated) 
3. Leukoplakic ( white patch) 
4. Erythroplakic ( red patch) 
5. Erythroleukoplakic ( combined red and white patch) 
OROPHARYNGEAL CARCINOMAS: 
           Tumour size is typically greater than that of anterior carcinomas and the 
proportion of cases with cervical and distant metastases at diagnosis is higher. 
Three of every four oropharyngeal carcinomas arise from tonsillar area or soft 
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palate; most other originate on the base of the tongue. The initial symptoms 
are usually pain or difficulty in swallowing with the pain being dull or sharp 
and frequently referred to the middle ear.
47 
METASTASES: 
            The metastatic spread of  carcinoma is largely through the lymphatics 
to the ipsilateral cervical lymph nodes and the consistency of the lymph node 
is usually stony hard, non tender and enlarged. If the malignant cells have 
perforated the capsule of the node  and invaded the surrounding tissues, the 
node will feel fixed or not easily movable. Ocassionally, contralateral or 
bilateral metastatic deposits are seen, and at least 2 % of patients have distant 
metastases at diagnosis. The most common sites of distant metastases are the 
lungs, liver and bones but any part of the body may be affected. 
                Carcinomas from the lower lip and oral floor tends to travel to the 
submental nodes; tumours from the posterior portions of the mouth travel to 
the superior jugular and diagastric nodes. Lymphatic drainage from the 
oropharynx leads to the jugulodigastric chain of lymphnodes or to the 
retropharyngeal nodes.
46 
DIAGNOSTIC AIDS: 
           Aids to oral examination include imaging and light technologies, vital 
tissue staining using toluidine blue, and computer-assisted cytology of oral 
brush biopsy specimens. 
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          Toluidine blue can be applied directly to suspicious lesions or used as an 
oral rinse.
23
 Use of 1% toluidine  blue has been mentioned due to the property 
of the dye to stain hyperchromatic nuclei
45
 . Positive retention of toluidine blue 
(particularly in areas of leukoplakia, erythroplakia, and uptake in a peripheral 
pattern of an ulcer) may indicate the need for biopsy. False-positive dye 
retention may occur in inflmmatory and ulcerative lesions, but false negative 
retention is uncommon.
23 
            ViziLite is a disposable chemiluminescent light source, approved by 
the US Food and Drug Administration (FDA) and used in conjuction with a 
standard visual examination and toluidine blue.
22
 Visual inspection is  carried 
out under chemiluminescent illumination to detect abnormal epithelial 
changes. Normal epithelium gives a  blue hue and altered epithelium appears  
“acetowhite” under chemiluminescent light.45 
            In exfoliative cytology, smears are stained by standard Papanicolaou’s 
technique and studied for changes of character of cell population and 
individual cells.
45
 In conclusion the author delivers that early evaluation of 
oral pre cancerous lesions can have a dramatic effect on oral cancer mortality 
rate and hence an attempt has been made to identify oral cancers in the early 
stages by more precise methods. 
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IMAGING: 
            Routine radiology, computed tomography (CT), nuclear scintiscanning, 
magnetic resonance imaging (MRI), and ultrasonography can provide 
evidence of bone involvement and can indicate the extent of some soft tissue 
lesions. Positron emission therapy (PET) using the radiolabeled glucose 
analog 18-florodeoxyglucose (18FDG) offers a functional imaging 
approach for the entire body. Imaging to determine bone involvement may 
include  and routine radiology (including dental radiographs for alveolar 
bone involvement), CT, bone scanning and nuclear scintiscanning. Soft tissue 
involvement of the antrum and nasopharynx can be assessed with CT and 
MRI. Each MRI image should include T1-weighted images, which 
demonstrate normal anatomy with detail and soft tissue defiition, and T2-
weighted images, which demonstrate the tumor in comparison with adjacent 
muscle and other soft tissues. CT and MRI also help in determining the status 
of the cervical nodes.
23 
            Paulina palasz et al ( 2017)
50
 has reviewed the contemporary 
diagnostic imaging of oral squamous cell carcinoma. The characteristic feature 
of malignant lesions in plain radiographs include – atrophy of cortical lamina, 
osteolytic defects – both single and multiloular with an initial osteosclerotic 
capsule. In later stages, the ridges of bone defects become sharp and the teeth 
lose their bony support at the site of infiltration. 
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In  panoramic radiographs detection of involvement of bone  has sensitivity of 
75% and specificity of 100% respectively.  
COMPUTED TOMOGRAPHY: 
            CT is a standard tool for detecting the primary tumours as well as their 
local bone infiltration. Contrast enhanced computed tomography can 
accurately determine lymph node metastases .The sensitivity of CT in 
detecting tumours is 41% - 82% ( specificity 82 – 100%) and in determining 
bone infiltration 63% - 80%( specificity 81 – 100%).In cancers localized in the 
retromolar triangle with the use of puffed cheek MDCT, the sensitivity and 
specifity of determining mandible and bone marrow involvement can be 
increased to 83% - 94%. Perfusion computed tomography is based on the 
increase in blood volume and blood flow in tumours. 
CONE BEAM COMPUTED TOMOGRAPHY: 
       CBCT is more accurate than panoramic radiography and comparable  to 
MRI, CT and bone scintigraphy. However, it is limited by a poor assessment 
soft tissues. 
CT FLUOROSCOPY GUIDED BIOPSY: 
       It is a minimally invasive imaging technique that enables a real time 
assessment. It can be used for taking biopsies of oral cancers. 
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MAGNETIC RESONANCE IMAGING (MRI): 
         The protocol of an MRI study includes the following sequences – T1, 
T2, STIR, TIRM, DWI, perfusion with and without a contrast agent. MRI 
enables the detection of very small lesions, assessment of local spread of the 
tumour, planning surgery, evaluation of complications that  can occur during 
and after surgery, involvement of bone marrow and bones as well as vessels 
and nerves. In case of micrometastases in the lymph nodes, DWI based MRI 
and hybrid methods can be helpful. Diffusion weighted  imaging is used for 
assessing lymph nodes 
SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY 
(SPECT): 
        SPECT allows for mapping metabolic activity of the tumour with the use 
of gamma radiation. The sources of radiation are isotopes such as 3-D 
99mTcDPD or 99mTechnetium methoxy isobutyl isonitrile 
POSITRON EMISSION TOMOGRAPHY: 
         PET with 18-fluorodeoxyglucose evaluates tissue metabolic activity. It is 
used when planning adjuvant treatment and predicting survival without 
recurrence.. Moreover, PET is used to look for primary tumour site when 
metastases are found earlier .  
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ULTRASONOGRAPHY: 
             Ultrasonography is used to evaluate superficial lesions, lymph nodes 
and to guide needle aspiration biopsies.(NAB). NAB is used in order to 
confirm metastatic lymph nodes. In oral cancer, intraoral USG with colour 
Doppler can also be used in order to assess the involvement of lymph nodes. It 
can show an increased vascularity within the tumour (blood flow) . 
             In conclusion the author emphasizes that it is crucial to be aware of 
the basic clinical data of patients and their tumours when interpreting the 
results of their imaging studies. The author further adds that all imaging 
modalities have their advantages and disadvantages and therefore the clinician 
must judiciously combine them in order to attain the highest possible efficacy 
and sensitivity, as it cam significantly improve patient outcomes. 
BIOPSY – ACQUISITION OF TISSUE SPECIMEN: 
          In addition to the standard biopsy techniques, tissue can be acquired for 
histopathology by using fine-needle aspiration (FNA) and exfoliative 
cytology. Open biopsy of enlarged lymph nodes is not recommended; in such 
cases, FNA biopsy should be considered. FNA also may aid the evaluation of 
suspicious masses in other areas of the head and neck, including masses that 
involve the salivary glands, tongue, and palate.
23 
           Oliver et al 2004
49
 presents an updated review of biopsies and 
discusses some of the potential problems with biopsy technique and how to 
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overcome them. If the reason for biopsy was to exclude malignancy a  biopsy 
of the ulcer to include some adjacent clinically normal epithelium would be 
desirable. The centre of larger tumours should be avoided as this is often 
necrotic and will not yield diagnostic material. 
          The author concludes that a little forward planning and thinking can 
greatly improve the diagnostic value  obtained. Careful handling of the tissue 
and prompt appropriate fixation will enable a confident histological diagnosis 
to be reached 
STAGING OF ORAL CANCER: 
          The American joint Committee on Cancer
3
 (AJCC) in cooperation with 
TNM committee for the International Union against for  Cancer, has brought 
out the sixth edition of the  AJCC manual for the staging of cancer in the 
year 2002. This classification is based on the premise that cancers of the same 
histologic site and histology and pattern share similar patterns of growth and  
similar outcomes. 
GENERAL RULES OF THE TNM SYSTEM: 
       The TNM  system is an expression of the anatomic extent of the disease 
and is based on the assessment of three components: 
T The presence or absence of primary tumour 
N The presence or absence of regional nodal metastases 
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M The presence or absence of  distant metastases 
The use of numerical subsets of the TNM components indicates the  
progressive extent of malignant disease: 
T0, T1, T2, T3, T4 
N0, N1, N2, N3 
M0, M1 
The following general rules apply to all sites: 
1. All cases should use the following tome guidelines for evaluating the 
stage: through the first course of surgery or 4 months whichever is 
longer. 
2. All cases should be confirmed microscopically for TNM classification.  
Rare cases that do not have a biopsy or cytology of the tumour can be 
staged but should be analysed separately and should not be included in 
survival analysis. 
3. Four classifications can be described for each site: 
 Clinical classification designated as cTNM 
 Pathologic classification designated as pTNM 
 Retreatment classification designated as rTNM 
 Autopsy classification designated as aTNM 
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DEFINITIONS OF TNM: 
Primary tumour: 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour 2cm or less in greatest dimension 
T2 Tumour more than 2cm and  less than 4cm in greatest dimension 
T3 Tumour more than 4cm in greatest dimension 
T4 Tumour invades through cortical bone, inferior alveolar nerve, floor of    
             the mouth or skin of the face i.e ., chin or nose 
T4a       Tumour invades through cortical bone , into deep (extrinsic ) muscles  
              of the tongue, maxillary sinus, skin of the face. 
T4b       Tumour involves masticator space, pterygoid plates, or skull base and  
              /or encases internal carotid artery 
REGIONAL LYMPH NODES: 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph nodes metastasis 
N1 Metastasis in single ipsilateral lymph nose , 3 cm or less in greatest  
            Dimension 
N2 Metastasis in single ipsilateral node more than 3 cm , but less than 6  
cm in greatest dimension; or in multiple ipsilateral lymph nodes , none more 
 than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes 
, none more than 6 cm in dimension 
N2a      Metastases in single ipsilateral node, more than 3 cm but less than 6  
            cm in greatest dimension 
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N2b      Metastases in multiple ipsilateral lymph nodes less than 6 cm in  
             greatest dimension 
N2c       Metastases in bilateral or contralateral lymph nodes none more than 6  
              cm in greatest dimension 
N3 Metastases in lymph node more than 6 cm in  greatest dimension 
DISTANT METASTASES: 
MX  Distant metastases can be assessed 
M0 No distant metastases 
M1 Distant metastases 
 
STAGE GROUPING: 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
 T1 N1 M0 
 T2 N1 M0 
 T3 N1 M0 
IVa      T4a      N0       M0 
 T4a      N1 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N2 M0 
 T4a      N2 M0 
IVB     AnyT   N3 M0 
 T4b AnyN   M0 
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IVC AnyT   AnyN   M1 
 
HISTOLOGIC GRADE: 
GX Grade cannot be assessed 
G1 Well differentiated 
G2 Moderately differentiated 
G3 Poorly differentiated 
 
RESIDUAL TUMOUR 
RX Presence of residual tumour cannot be assessed 
R0 No residual tumour 
R1 Microscopic residual tumour 
R2 Macroscopic residual tumour 
In ,reviewing the staging systems, several changes in the T classifications as 
well as stage groupings are made to reflect current practices of treatment, 
clinical relevance, and contemporary data. Uniform T staging for oral cavity. 
oropharynx, salivary and thyroid cancers greatly simplifies the system and will 
improve compliance by the clinicians. 
TREATMENT OF ORAL CANCER: 
               The principal objective of treatment is to cure the patient of cancer 
Surgery and radiation are used with curative intent in the treatment of oral 
cancer. Chemotherapy is an adjunct to the principal therapeutic modalities of 
radiation and surgery and is now standard combined therapy in management of 
advanced disease. Either surgery or radiation may be used for many T1 and T2 
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lesions; however, combined radiation and chemotherapy with or without 
surgery is usually employed for more advanced disease.
23 
             Jelena Prelac et al ( 2014)
28
 has done a review of the different 
modalities of treatment of oral cancer. The discussion focuses on the specific 
effects of the different treatment modalities which includes surgery, 
chemotherapy, radiotherapy combination therapy , targeted therapy on the 
patient in different stages of cancer. In general, single modalities are more 
commonly used in early stage SCC (Stages I & II) and carcinoma-in situ 
(CIS), while patients with advanced disease (Stages III & IV) are treated with 
a combination of therapies . Tumour characteristics such as site, proximity to 
bone, the depth of invasion, and stage (tumour size, lymph node involvement, 
and risk of metastasis) are considered along with the age of the patient, co-
morbidities, compliance to treatment, and the desire to make lifestyle changes. 
SURGERY AND NECK DISSECTION: 
           The intent of surgery is to completely remove cancerous tissue, leaving 
histologically normal tumour margins while attempting to preserve normal 
tissue and function .  Positive or suspicious lymph node involvement may 
require a radical neck dissection, while elective neck dissections are 
sometimes undertaken even when the lymph nodes are negative. 
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CHEMOTHERAPY: 
            The purpose of Chemotherapy is to destroy dividing abnormal cancer 
cells rapidly in order to manage spread and metastasis. The delivery of CT can 
be divided into three categories: induction CT (before surgery), concurrent 
CRT (in conjunction with radiation treatment), and adjuvant CT (after surgery 
and/or radiation). Induction therapy is used primarily in patients who have 
advanced stage disease and nodal involvement, and in patients at the greatest 
risk of recurrence, second primary tumours, and metastases. By combining a 
chemotherapeutic agent with radiation, the efficacy of RT is increased and 
results in better tumour control and survival rates. 
RADIOTHERAPY: 
         The intent of RT is to destroy DNA in dividing cancer cells in a localized 
region while preserving adjacent tissue and function. The use of surgery and 
postoperative RT is a common combination in oral cancer treatment, used for 
large tumours and when surgical margins are positive for cancer. RT 
combined with CT is the preferred treatment of oropharyngeal cancers. The 
two main types of RT are external beam radiation and brachytherapy 
Brachytherapy, a form of internal radiation, involves the precise surgical 
placement of a radioactive insert into the tumour, directly treating the 
tumour. However, it is restricted by the size of the field that it can target 
effectively.  External beam radiation is provided as a daily outpatient 
treatment, over the course of about 6 weeks, using a linear accelerator 
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(LINAC) that focuses radiation on the tumour site. While it is a very effective 
cancer treatment, it also unfortunately affects the normal surrounding tissue 
and the normal tissue through which it travels to reach the tumour site. 
TRADITIONAL AND CURRENT RADIOTHERAPY: 
          In traditional external beam radiation, “shrinking fields” are used  in 
which the most sensitive organs are irradiated fist and blocked, treating the 
overlying low-risk organs next with more superficial radiation. The high-risk 
areas surrounding the tumour, grossly involved lymph nodes, and the tumour 
itself are treated last with the highest dose of tolerable radiation Radiation 
doses vary; generally 1.8 to 2.0 Gray (Gy) are delivered daily, 5 days a week, 
Monday to Friday. Treatment continues over the course of 6 weeks for a total 
of 30 fractions, until a maximum of 60 Gy is provided. 
Current approaches to RT include 3-dimensional conformal radiation therapy 
(3D-CRT), intensity modulated radiation therapy (IMRT), and volumetric 
arc therapy (VMAT).These techniques have been developed both to deliver 
radiation to the tumour more precisely while protecting normal tissues and to 
allow for flexibility to alter the dose. 3D-CRT delivers beams from 3 
dimensions versus the traditional 2, while IMRT provides even greater control 
by using beams of different intensities from a variety of dimensions. VMAT is 
a further extension of IMRT, delivering a higher dose faster to the whole 
tumour volume simultaneously either in a single arc or series of arcs. Two 
more recent advances in RT are altered fractionation and concurrent systemic 
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chemotherapy. Altered fractionation refers to changes in the dose per fraction, 
the number of fractions delivered per day, and the overall duration of 
treatment. Altered fractionation can further be divided into hyperfractionation 
and accelerated fractionation. Hyperfractionation provides smaller doses per 
treatment but delivers 2 fractions per day for the same or longer time period so 
that a greater overall dose can be delivered to the tumour. In contrast, 
accelerated fractionation delivers the total dose over a shorter time period, 
usually with greater doses per fraction or multiple doses per day. By 
increasing irradiation intensity, accelerated fractionation reduces 
the risk of repopulation of cancer cells, which may follow delays in treatment. 
SIDE EFFECTS: 
The short-term effects of RT are more well known than the late and long-term 
effects. In the short term, RT can result in mucositis (more than 50% of 
patients), loss of taste, hoarseness and pain, as well as dermatitis, radiation 
burn, and an increased susceptibility to infection. For more than 60% of 
patients, xerostomia will be long term, a major concern for dental 
professionals as it significantly increases a patient’s risk of caries and 
periodontal disease. Other long-term effects on both soft and hard tissue 
include poor wound healing, taste impairment, diffiulty swallowing, tissue 
fibrosis, osteoradionecrosis (ORN), and telangiectasia. ORN, chronic ulcers, 
and telangiectasia may not appear until many years after RT has been 
completed. Approximately 40% of patients who receive CRT suffer 
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from severe late toxicity.  The severe toxic effects include hypomagnesaemia, 
myelosuppression, neutropenia, and general haematologic toxicity, as well as 
more common outcomes such as mucositis, dermatitis, stomatitis, and 
xerostomia. 
          In conclusion, the author emphasizes that   the purpose of monitoring 
patients following therapy is to a) provide care for the sequelae of treatment 
side effects; b) to coordinate care between specialists and primary care 
providers to  ensure that both oral and overall health needs are met; and c) to 
prevent and identify recurrence or the development of a second primary 
tumour. 
ADVANCES IN EXTERNAL BEAM RADIOTHERAPY:  
            Dirk Van Gestal et al ( 2013)
12
 has reviewed  the advances in  
external beam radiotherapy or treatment of head and neck cancer.  The 
discussion gives us an overview of the recent evolution of external beam 
therapy, which had initially began with 2D CRT, 3D CRT and then has 
evolved as static beam IMRT, rotational beam IMRT, stereotactic RT which 
includes cyber knife and particle RT which includes protons IMPT and heavy 
ions which include carbon ions. In IMRT the use of multileaf collimators ( 
MLC) which causes a rapid change in field configuration and the use of 
rotational intensity modulated radiotherapy resulting in more conformal dose 
distribution has also been discussed. 
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        Mehta et al (2010),
37
 has reviewed the basic concepts  of radiotherapy, 
and the recent advances and has emphasised that approximately 65% of all  
patients require radiotherapy as the sole treatment modality and / or in 
combination with chemotherapeutic drugs and surgery, however a huge gap 
between the supply and demand of infrastructure and facilities exists, which is 
of concern. A brief mention has been made about the principles of radiation 
physics, biology of radiation therapy,  different modes of radiotherapy and 
about the acute and late toxic reactions which are associated with 
radiotherapy. 
             Kara . M . Bucci et al (2005)
38
 has reviewed the advances in 
radiotherapy and the way these advances have changed the way the common 
neoplasms are treated now and in the future. A discussion of the different 
modes of radiotherapy including 3D CRT, IGRT, IMRT, the pitfalls of each of 
these methods, which has driven us to a more novel 4 dimensional 
radiotherapy mode has also been done. The advances in radiotherapy in 
treating prostrate cancer, head and neck cancer, breast cancer , biological 
therapies, targeted therapies has also been mentioned. To conclude, the 
advances in molecular profiling and new imaging techniques may eventually 
help those fortunate patients in future. 
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Fig 1: Linear Accelarator Machine 
DEFINING THE TUMOUR AND TARGET VOLUMES FOR 
RADIOTHERAPY: 
            Neil G Burnrt et al ( 2004)
46
 have proposed a review article to define 
the tumour and target volumes for radiotherapy. There are three main volumes 
to be considered in radiotherapy planning. The first of these two volumes is 
the position and extent of the primary tumour; this is known as the gross 
tumour volume (GTV). The second volume surrounds the GTV and describes 
the extent of microscopic, un-imageable tumour spread; this is known as the 
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clinical target volume (CTV). Once these two volumes are established, the 
third volume, the planning target volume (PTV), which allows for 
uncertainties in planning or delivery, must be added, and the normal tissue 
structures in the vicinity of the target must be considered. 
GROSS TUMOUR VOLUME: 
           This is the easiest volume to define,and  is essentially the gross 
demonstrable location and extent of tumour, can be palpated or imaged.site, 
involves lymph nodes or spread into adjacent soft tissue. Typically, it is 
considered that the GTV corresponds to the part of the tumour where the 
tumour cell density is highest. 
 CLINICAL TARGET VOLUME: 
             The CTV contains the demonstrable GTV plus a margin for sub-
clinical disease spread  which cannot be imaged.  This volume must be 
adequately treated if cure is to be achieved. It is assumed that the tumour cell 
density in the CTV is lower than in the GTV and consequently the 
radiotherapy dose may be lower. It  requires clinical assessment of risk and 
extent of spread, normally based on historical series rather than the extent of 
tumour quantified in an individual patient. 
PLANNED TARGET VOLUME: 
          The PTV is really a geometric concept designed to ensure that the 
radiotherapy prescription dose is actually delivery to the CTV. It is a volume 
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related to the isocentre of the linear accelerator rather than to the anatomy of 
the patient. For this reason, the PTV may extend beyond anatomical barriers 
such as bony margins, and may even extend outside the patient. 
ORGANS AT RISK:  
          ORs are normal tissues whose radiation sensitivity influences treatment 
planning or the prescribed radiation dose. Both systematic and random errors 
apply to OAR just as much as to the CTV. In that case, a margin should be 
added to the OR, which is analogous to the PTV margin around the CTV, and 
generates the PRV. 
             In conclusion the author delivers that the concepts of GTV, CTV and 
PTV have been enormously helpful in allowing radiation oncologists to 
develop treatment protocols and all of these volumes are 
crucially dependent on high quality imaging. 
 
  Fig 2: Radiotherapy Planning Volumes 
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            Anca Ligia Grosu et al, ( 2005)
4
 has reviewed the various target 
volumes and had also discussed about new concepts called biological target 
volume. Techniques such as PET, SPECT and MRS permit the visualisation of 
molecular biological pathways in tumours 
          To conclude the author emphasizes that target volume definition  is an 
interactive process and  based on radiological (and biological) imaging, the 
radiation oncologist has to outline the GTV, CTV, ITV , PTV and BTV. 
3 DIMENSIONAL CONFORMAL RADIOTHERAPY: 
          Zimmerman( 1998)
18
 has reviewed the basic principles about 3D CRT 
which explains the concept of Gross Tumour Volume, Clinical Target 
Volume, Planned Target Volume, various methods of immobilization  before 
radiotherapy, ideal positioning of the target volume, Beam modelling, 
calculation of dose distribution, Dose-Volume Histograms, the normal tissue 
complication probability, simulation and treatment procedure. To conclude, 
the author has delivered that computer controlled treatment delivery will help 
to reduce treatment and planning time and the treatment quality will be further 
improved. 
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                                      Fig 3: Planning in 3D CRT 
INTENSITY MODULATED RADIOTHERAPY: 
               Bin S The et al (2017)
7
 has reviewed the basics of Intensity 
modulated radiotherapy and describes it as a revolutionary concept. In IMRT 
the use of multiple treatment fields, choice of beam energies and modalities, 
weighting of different beams as well as the use of wedges and tissue 
compensators, has accomplished the goal of  keeping the radiation dose to the 
surrounding normal structures below tolerance level. IMRT combines two 
advanced concepts to deliver 3D conformal radiation therapy: A) inverse 
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treatment planning with optimization by computer and B) computer-controlled 
intensity modulation of the radiation beam during treatment. 
               A radiation oncologist defines the tumour and the radiation dose   
that he wants around the tumour. The computer, using a mathematical 
optimization technique known as simulated annealing, will determine the 
optimal treatment fields. In addition, one can also define where one does not 
want the deposition of radiation. IMRT system, starts with the target volume, 
where it places a uniform, conformal dose around the tumor. The computer 
then “backprojects” through the patient’s tissue to the linear accelerator source 
and finds the nonuniform radiation exposure that must be delivered by the 
linear accelerator to give this conformal dose pattern. The system, like the CT 
scan, uses a slice-by-slice, arc-rotation approach. 
          The author concludes by saying that IMRT is especially promising in 
decreasing acute treatment-related toxicity in either definitive or palliative 
irradiated cases. 
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                                     Fig 4:Primary tumor in IMRT 
COMPENSATORS  IN IMRT: 
           A.Bakai et al ( 2001)
6
 have described about the different compensators 
used in IMRT  which includes the use of multi- leaf collimators (MLC) for 
beam shaping. In addition to the use of MLC’s there are other compensators 
used which are highly absorbing materials of  varying thickness according to 
the fluence distribution of varying fields. The author has concluded saying that 
the compensators could be made much thinner and therefore lighter which 
would make their usage in  everyday’s clinical routine practicable.  
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IMAGE GUIDED RADIOTHERAPY: 
              Lei Xing et al ( 2006)
35
 has delivered an overview on image guided 
radiotherapy which describes IGRT as an advanced imaging technology to 
better define the tumour target and is the key to reducing and ultimately 
reducing the uncertainities. The review focuses on the IGRT development in 
four major areas, including (1) biological imaging tools for better definition of 
tumour volume (2) time resolved 4D imaging techniques for modelling the 
intra fraction organ motion (3) on board imaging system or imaging devices 
registered to the treatment machines for inter fraction patient  localization (4) 
new radiation treatment planning or treatment schemes incorporating the 
information obtained from the mew imaging techniques. Tumour target 
volume delineation could be done by imaging techniques including CT, MRI, 
specialized MRI techniques and ultrasound. The role of CBCT in patient 
localization and dose verification has also been explained. To summarize, the 
review focuses on the recent efforts put forth in removing the uncertainty  in  
the definition of the target volume and un the determination of the position of 
the mobile and often deformable organs. 
METHODS OF IMMOBILIZATION IN DIFFERENT MODES OF 
RADIOTHERAPY 
          For repeated doses of radiation to be applied to the site of treatment, the 
patient and the area of treatment are immobilized, but using various techniques 
and materials, including head holders; bandages; laser positioning, using 
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head and neck “landmarks”or tattoos; and custom acrylic shells (mold room 
technique). Custom shells provide the best means of immobilization and 
positioning of patients that are critical in IMRT and IGRT. These techniques 
may be combined with an oral device to position the mandible, 
allowing the maxilla or mandible to be moved into or out 
of the radiation field.
23 
ACUTE AND LATE TOXICIY EFFECTS OF RADIATION: 
           Supriya Mallick et al ( 2015)
57
 has reviewed the pathophysiology, 
prevention and management of oral mucositis which is a major limiting acute 
side effect of radiotherapy of head and neck cancer. The pathophysiology 
includes five phases , the initiation phase,( DNA strand breaks and damage to 
the cells), activation phase ( role of proinflammatory cytokines),signalling and 
amplification phase ( activation of ceramide and capsases pathways), 
ulceration phase (breach in the mucosa) and finally the healing phase. The first 
sign of mucositis is erythema (Grade I) which starts by the end of second 
week, followed by focal areas of desquamation (Grade II) which develop 
during the third week of RT, which then progresses to confluent mucositis 
(Grade III) by fourth to fifth week. Various methods to prevent the 
development of mucositis like use of mouthwashes, various topical analgesics, 
sucralfate, GM – CSF, cryotherapy, palifermin, pentoxyphylline, glutamine, 
beta – carotene, prostaglandins have also been mentioned briefly. To conclude 
, the author says that adequate management and treatment may improve 
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patient compliance which may translate into better disease control and 
survival. 
 
Fig 5: Mucositis in Oral Cavity 
           Fleta N Brey et al (2007)
19
 have in their review article have focussed 
on the acute and chronic cutaneous reactions to ionizing radiation. Acute 
changes include erythema and pain and occur within 90 days. Acute reactions 
start with erythema, edema, pigmentary changes and depilation that correlate 
with the amount of radiation exposure. Grade 1 changes include dry 
desquamation with a generalized erythema.  Pruritus, epilation, scaling and 
depigmentation can also occur. With grade 2, there is brisk erythema or 
localized focal sloughing of the epidermis  With moist desquamation, the 
epidermal layer is lost and there is a high propensity for infection. The 
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reaction peaks in 1–2 weeks with subsequent healing.  Grade 3 presents with 
extensive moist desquamation outside of skin folds . With grade 4, ulcerations, 
hemorrhage and skin necrosis are likely to occur. Chronic radiation dermatitis 
is unlikely to self-repair and may remain indefinitely.   The defining features 
of the late-stage are fibrosis, atrophy, hypo- or hyperpigmentary changes and 
the development of cutaneous malignancies. Significant cutaneous injury is 
characterized by persistent dyspigmentation, atrophy, and telangiectasia.The 
management includes use of low to mid potency topical steroids, hydrophilic 
moisturizers, use of hydrogel and hydrocolloid dressings and mesenchymal 
stem cell injections to increase healing. 
             To conclude, the author emphasizes there is still a great need for novel  
and developing therapies and supportive care and appropriate wound care 
continue to be the mainstays of treatment at this time. 
 
Fig 4: Skin Reactions after Radiotherapy 
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            Roberto pinna et al (2015)
52
 have presented a review article which 
highlights the salivary gland hypofunction and xerostomia after irradiation in 
head and neck cancer patients which severely hampers the quality of life of 
these patients. The pathophysiology says that the damage to the oral cavity has 
been strongly related to the radiation dose, fraction size, volume of irradiated 
tissue, fractionation scheme, and type of ionizing irradiation, but on the other, 
it may be difficult to distinguish changes caused by radiotherapy itself from 
those related to the malignant disease. The submandibular gland is less 
radiosensitive than the parotid gland. Salivary electrolytes are altered, with an 
increase in the concentrations of sodium, chloride, calcium, and magnesium, 
while potassium is only slightly affected.  Saliva also reduces the buffering 
capacity in irradiated patients due to a reduction of bicarbonate concentration 
in parotid saliva. Saliva becomes, moreover, highly viscous, and reduces its 
pH from about 7.0 to 5.0 The management includes the use of candy 
containing xylitol or sorbitol, parasympathomimimetic  drugs like cevimeline 
or pilocarpine , use of cholagogue anathol trithione and yohimbine. 
           In conclusion the author says the best approach to manage the 
radiotherapeutic patient begins with a careful clinical assessment of the 
individual case, followed by preventive therapy aimed to reduce oral 
complications when possible and hence  the clinician must keep this kind of 
patients under careful control in order to palliate the symptoms of xerostomia 
and improve their quality of life. 
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STUDIES CONDUCTED FOR COMPARISON OF TOXICITY 
PROFILES: 
        Ibrahim Awad et al ( 2013)
26
 have conducted a study to evaluate the 
wedged tangential beam three dimensional conformed radiotherapy compared 
to the previously used ( 5 years) two dimensionally planned radiotherapy for 
post mastectomy breast cancer patients. They were assessed for PTV and 
organs at risk with a prescribed total dose of 50 Gy for 25 fractions. The 
results showed that the mean percentage  dose  to the contralateral breast to the 
prescribed dose was 8.2% for 3D CRT compared to 10.4% for 2D CRT 
tangential field techniques. On conclusion the author has confirmed that the 
tangential beam 3D CRT planning demonstrated a significantly better 
homogeneity index for the PTV of post mastectomy breast cancer patients 
           Rudd .C .Wortel(2015)
53
  et al have conducted a study to assess and 
compare the acute toxicity profiles among prostrate carcinoma patients. The 
purpose of the study was to compare dose distribution to organs at risk and 
acute  gastrointestinal and genitourinary toxicity levels of patients treated to 78 
Gy  with either IG – MRT or 3D CRT. IG – MRT resulted in significantly 
lower overall RTOG grade > 2 GI toxicity, with a p value of 0.002 and overall 
GU grade of  > 2 toxicity  with a p value of 0.009.  Hence there is a clinically 
meaningful reduction in dose to organs at risk and acute toxicity levels was 
observed in IG – MRT patients as a result of improvement in technique and 
tighter margins. 
                                                                  Review of literature 
 
47 
 
          Evangelia Paponi et al ( 2011)
16
 have carried out  a study to evaluate 
the subjective and objective long term swallowing function, and to relate 
dysphagia to the radiation dose delivered to the critical anatomic structures in 
the head and neck cancer patients treated with intensity modulated 
radiotherapy ( +/- chemotherapy) , using a midline protection contour.Normal 
tissue effects were graded according to the Radiation Therapy Oncology 
Group (RTOG)/European Organization for Research and Treatment of Cancer 
(EORTC) radiation morbidity scoring criteria. Swallowing dysfunction and 
dysphagia were additionally graded with subjective patient reported and 
objective observer assessed instruments. The results showed that at the 32 
month follow up evaluation, persisting swallowing dysfunction grade 3 was 
subjectively and objectively observed in 1 patient. The 5 year local control rate 
of the cohort rate was 75%, with no medial marginal failures observed. Based 
on the results it was concluded that sparing the swallowing structures by 
IMRT is relatively safe in terms of avoidance of persistent grade ¾ dysphagia 
and local disease control. 
           Tim J Kruser et al ( 2013)
59
 have conducted a study to compare the 
acute haematological and mucosal toxicities in patients undergoing head and 
neck radiotherapy by 3D CRT, IMRT and helical tomotherapy. This analysis 
was limited to 178 patients receiving ≥ 60 Gy with concurrent weekly 
cisplatin. Radiation delivery used 3D-CRT in 41 patients (23%), conventional 
IMRT in 56 patients (31%), and helical tomotherapy in 81 patients (46%). 
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Acute mucositis rates, weekly hematologic parameters, and ability to deliver 
planned chemotherapy cycles were examined for each patient during their 
course of chemoradiotherapy. Analysis showed patients were well balanced 
with regard to sex, age, and stage. The results showed that among oropharynx 
patients treated with 3D-CRT, grade 2 mucositis occurred in 12.5% and grade 
3 in 83.3%; among LINAC-IMRT patients grade 2 mucositis occurred in 40% 
and grade 3 in 57.5%; and among helical tomotherapy-treated patients grade 2 
mucositis occurred in 30% and grade 3 in 70%. Chemotherapy has been 
demonstrated to increase the risk of mucosal Grade 3 toxicity approximately 4 
times over radiation alone, and is equivalent to an additional 6.2 Gy to the oral 
mucosa. Through six weeks of chemoradiotherapy, the median decline in 
hemoglobin was 15.6%, the median decline in platelets was 30.6%, and the 
median decline in leukocytes was 51.5%, but these drops were not 
significantly different between treatment cohorts.  
           Gopa Gosh et al (2016)
20
 have conducted a study to compare the 
toxicity profile of 3D CRT and IMRT modes of radiotherapy in head and neck 
cancer patients. A total of 80 patients with proven head and neck cancer who 
underwent radiotherapy on linac 2300 C/D machine were included in the 
study, IMRT group and 3D-CRT group comprised of 40 patients each. The 
3D-CRT group demonstrated signifiantly more acute toxic effects compared 
with the IMRT group . Acute Grade 3 or greater toxic effects to the skin 
occurred in 5 of 40 (12.5%), patients in the 3D-CRT group compared with 3 of 
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40 (7.5%) patients in the IMRT group. Acute Grade 3 or greater toxic effects 
to the mucous membranes occurred in 23 of 40 (57.5%) patients in the 3D-
CRT group and only 16 of 40 (40%) patients in the IMRT group. Statistically 
significant dysphagia developed in 34 of 40 (85%), patients in 3D-CRT group 
compared with 23 of 40 (57.5%) patients in IMRT group, while statistically 
significant xerostomia developed in 29 of 40 patients in 3D-CRT group 
(72.5%), compared with18 of 40 (45%) patients in IMRT group. 
            Gupta Tejpal et al (2010)
25
 have done a systematic meta analysis on 
the various studies conducted  to analyse the toxicity profiles of 3D CRT and 
IMRT modes of treatment. In the first study, 69 patients with early 
oropharyngeal cancer (T1-2, N0-1) on accelerated, hypofractionated IMRT 
regimen , receiving a dose of 66 Gy to primary tumor and involved nodes and 
54–60 Gy to subclinical disease in 30 fractions over 6 weeks were followed up 
for 2.8 years. The 2- year estimated localregional failure rate was 9%. 
Maximal late toxicities ≥ grade 2 were dermatitis (12%), mucositis (24%), 
salivary gland toxicity (67%), esophagitis (19%), and osteoradionecrosis (6%). 
Grade 2 or worse xerostomia was observed in 55% of patients at 6 months but 
reduced to 25% and 16% at 1-year and 2-years respectively. 
        Vergeer et al
62
  have done a large prospective non-randomized 
comparison of conventional radiotherapy (150 patients) with IMRT (91 
patients) and Patient-rated xerostomia, RTOG acute and late xerostomia, and 
QOL scores were measured at baseline (pre-radiotherapy) and at specified 
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post-radiotherapy intervals. The use of IMRT resulted in a significant 
reduction of the mean parotid dose (27 vs 43 Gy; P < 0.001). At 6-months, 
41% patients treated with IMRT reported moderate or severe xerostomia 
compared with 67% patients treated with 3D-CRT (P < 0.001). During 
treatment, significantly more patients in the 3D-CRT group encountered worse 
acute xerostomia and mucositis. At 6-months, 32% patients treated with IMRT 
had ≥ grade 2 RTOG late xerostomia compared to 56% patients treated with 
3D-CRT (P = 0.002). 
            Micheal  T Spiotto et al  (2014)
42
  have done a study to compare the 
outcome of patients treated with 3D CRT and IMRT with or without 
simultaneous integrated  boost during Concurrent chemoradiation  for locally 
advanced head and neck cancers. The study was conducted between 1993 and 
2012 with  379 patients with non-metastatic Stage III-IV head and neck 
squamous cell cancer  treated with concurrent chemoradiation using 3D-CRT 
(n = 125), IMRTseq (n = 120) and IMRT +SIB ( Simultaneous Integrated 
Boost) (n = 134).The results showed that Patients treated with any technique 
had similar rates of 2y local control, 2y regional control, 2y progression free 
survival and 2y overall survival. Patients treated with IMRT +SIB had lower 
rates acute toxicity according to Grade 3 or greater mucositis (3D-CRT: 44.0% 
vs. IMRTseq: 36.7% vs. IMRT +SIB: 22.4%; P,.0001), dermatitis (3D-CRT: 
44.0% vs. IMRTseq: 20.0% vs. IMRT +SIB: 7.5%; P,.0001) and feeding tube 
placement during radiotherapy (3D-CRT: 80.0% vs. IMRTseq: 50.8% vs. 
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IMRT +SIB: 44.0%; P,.0001) as well as late toxicity as measured by feeding 
tube use (P,.0001) and tracheostomy use ( P,.0001). On multivariate analysis, 
IMRT +SIB predicted for less mucositis, dermatitis and feeding tube use 
compared to 3DCRT and for less dermatitis compared to IMRTseq. 
           Ajay Singh Choudary et al (2017)
1
 have conducted a study 
comparative study of toxicities during treatment with IMRT Versus 3DCRT in 
locoregionally advanced Head and Neck Carcinoma. A total of 150 patients of 
histologically confirmed stage III to IVB squamous cell carcinoma of the oral 
cavity and oropharynx of either sex were evaluated in the study from July 
2015 to June 2016; 58 in IMRT group and 92 in 3DCRT group. All patients 
received 70 Gy in 35 fractions with 2 Gy per fraction in both groups with 
6MV photon beam concurrent with weekly cisplatin 30 mg/m2. The results 
showed that after median follow-up of 18 months (range, 12 to 24 months), 
3D-CRT group demonstrated significantly more acute toxic effects compared 
with the IMRT group. Significantly higher grade III or worse acute mucositis, 
dysphagia, acute and late xerostomia occurred in 57.6%, 84.8%, 71.7% & 63% 
of patients in 3DCRT group compared with 39.7%, 56.9%, 39.7% & 20.7% of 
patients in IMRT group (P-value 0.23, <0.001, <0.001 and <0.00respectively). 
Hence IMRT is associated with decreased early and late toxicities as compared 
to 3DCRT.it offers better normal tissue sparing, and better quality of life.      
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MATERIALS AND METHODS 
        The present study attempts to assess and compare the acute and chronic  
toxicity profiles due to  radiotherapy  in head and neck cancer patients 
undergoing 3D CRT, IMRT and IGRT modes. 
TYPE OF STUDY: Prospective study 
SAMPLE SIZE : 60 
STUDY PERIOD: January 2017 to November 2017 
PLACES CONDUCTED: 
1. Dr. Rai Memorial Cancer Treatment Centre 
2. Billroth Hospitals, Shenoy nagar, Chennai 
3. V.S. Hospitals  - Cancer treatment centre, Chetpet, Chennai 
STUDY POPULATION: 
1. 20 patients with head and neck cancer undergoing 3D CRT mode of 
radiotherapy 
2. 20 patients with head and neck cancer undergoing IMRT mode of 
radiotherapy 
3. 20 patients with head and neck cancer undergoing IGRT mode of 
radiotherapy. 
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INCLUSION CRITERIA: 
1. Patients diagnosed with squamous cell carcinoma of 
oropharynx,nasopharynx, oral cavity, hypopharynx and planned for 
radiotherapy. 
2. Staging T1 – T4,N0 – 2c,M0. 
3. Patients receiving 50 – 70 Gy, with or without concurrent 
chemotherapy. 
4. No prior radiotherapy. 
5. Kornofsky Performance Scale more than 70. 
 
EXCLUSION CRITERIA: 
1. Histopathologically proven cancer other than squamous cell 
carcinoma. 
2. Prior radiotherapy. 
3. Kornofsky performance Scale less than 70. 
 
MATERIALS USED: 
1) Sterilized set of mouth mirror, probes, kidney trays, metallic 
scale, divider, vernier callipers, graduated saliva collectors. 
 
ETHICAL APPROVAL: 
 Ethical clearance was obtained from the Institutional review board. 
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METHODOLOGY: 
           A prospective analysis of a total of 60 patients to undergo 3D – 
CRT, IMRT and IGRT  for treatment of squamous cell carcinoma in the head 
and neck region are to be selected. All patients were treated on linac 2300C/D 
machine, with immobilization in supine position using a customized 
thermoplastic device. Treatment planning involved Computerized 
Tomography Scan of the area of interest, followed by delineation of various 
target volumes like Gross tumour Volume(GTV),Clinical Target 
Volume(CTV),Planning Target Volume(PTV) and Organ at Risk volumes. 
The delineation of various volumes are done as per consensus guidelines. The 
ICRU report 50 from 1993 and ICRU report 62 from 1999 standardised the 
nomenclature used for three-dimensional conformal treatment planning 
and thus gave the community of radiation oncologists a consistent language 
and guidelines for image based target volume delineation. 
             The gross tumour volume (GTV) is the macroscopic (gross) extent of 
the tumour as determined by radiological and clinical investigations 
(palpation, inspection). The GTV-primary (GTV-P) defines the area of the 
primary tumour and GTV-nodal (GTV-N) the macroscopically involved 
lymph nodes (Anca Ligia Grosu et al). The GTV was  obtained by 
summarising the area outlined by the radiation oncologist in each section and 
was  multiplied by the thickness of each section. This  extension of the GTV is 
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of major importance for the treatment strategy . The delineation of GTV was   
based on the data obtained from CT and MRI. 
          Clinical Target Volume: The GTV, together with the surrounding 
microscopic tumour infiltration constituted the primary clinical target volume 
CTV (CTV-P). which  included the tumour bed, which has to be irradiated 
after a complete macroscopic tumour resection, in both R0 (complete 
microscopic resection) and R1 (microscopic residual tumour on the margin of 
the tumour bed) situation. As the margins between CTV and GTV are  not 
homogenous, they are adjusted to the probable microscopic tumour spread. 
CTV dose is calculated as  CTVdose = GTVdose + 10-20mm margin 
          Internal Target Volume: The ITV encompassed the GTV/CTV plus 
internal margins to the GTV/CTV, caused by possible physiological 
movements of organs and tumour, due to respiration, pulsation and variation 
of tumour size. In most cases the observation is impossible or difficult. 
         Planning Target Volume: The planning target volume (PTV) 
incorporated the GTV/CTV plus margins due to uncertainties of patient setup 
and beam adjustment; due to variations in patient positioning during 
radiotherapy and organ motility. The PTV dose is calculated as  
  PTVdose = CTVdose + 3 to 5 mm 
         After delineating the various target volumes and calculating the dose the 
fractionation is planned such that the total dose in case of squamous cell 
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carcinomas is between 50 – 70 Gy/ 30 – 35 daily  fractions, such that each day 
the patient would receive 180cGy – 200cGy. 
Planning Technique:  
3D CRT: The field was chosen to optimize dose coverage, and respect normal 
tissue tolerance with a single isocentre technique, avoid junction through gross 
disease. The energy  is delivered through 6 MV photons. 
IMRT: This includes 6 -9 coplanar fields and energy is delivered through 6 
MV photons. The beam intensities are modulated or non uniform in that they 
resulted in a sharper space dose gradient than 3D CRT technique. The field 
size, gantry angles and other beam characteristics are well defined to achieve a 
desired dose distribution. 
IGRT: The target volume delineation is done in the same manner as that of 
IMRT, but additionally frequent imaging was done during the course of 
radiotherapy, and these images are compared with the reference images taken 
during simulation and hence radiation beams are adjusted to more precisely 
target the radiation dose to the tumour. 
        After a cycle of radiotherapy is delivered by one of the three means the 
patients were observed to develop toxicities which included mucositis, skin 
reactions, xerostomia and dysphagia.  The toxicity patterns (grades of 
mucositis, skin reaction, dysphagia, xerostomia)   developing within 90 days 
from the beginning of RT (acute toxicity) are assessed according to Radiation 
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Therapy Oncology Group (RTOG) and European Organisation for the 
Research and Treatment of Cancer (EORTC) criteria. RT toxicity developing 
after 90 days (chronic/ late toxicity) is graded with the same scale for late 
sequelae (Gopa Gosh et al, 2016) The grading according to the RTOG criteria 
for acute and chronic toxicities are as such: 
   RTOG ACUTE Radiation morbidity 
Tissue Grade 1 2 3 4 
Skin Follicular, faint or dull 
erythema/epilation/dry 
desquamation/decreased 
sweating 
Tender or bright 
erythema, patchy moist 
desquamation/moderate 
edema 
Confluent, 
moist 
desquamation 
other than 
skin folds, 
pitting edema 
Ulceration, 
hemorrhage, 
necrosis 
Mucous 
membrane 
Irritation/may 
experience mild pain 
not requiring analgesic 
Patchy mucositis that 
may produce a 
serosanguinous 
discharge/moderate 
pain requiring 
analgesia 
Confluent 
fibrinous 
mucositis/may 
include severe 
pain requiring 
necrotic 
Ulceration, 
hemorrhage, 
necrosis 
Salivary 
gland 
Mild mouth 
dryness/slightly 
thickened saliva, may 
have slightly altered 
taste such as metallic 
taste 
Moderate to complete 
dryness/ thick, sticky 
saliva/markedly altered 
taste 
None Acute 
salivary 
gland 
necrosis 
Pharynx & 
oesophagus 
Mile dysphagia or 
odynophagia/may 
require topical 
anesthetic or non – 
narcotic analgesics/may 
require soft diet 
Moderate dysphagia or 
odynophagia/may 
require narcotic 
analgesics/ may require 
puree or liquid diet 
 Severe 
dysphagia or 
odynophagia 
with 
dehydration 
or weight loss 
> 15% from 
pretreatment 
Complete 
obstruction, 
ulceration, 
perforation, 
fistula 
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baseline 
requiring NG 
feeding tube, 
IV fluids. 
  
 
RTOG/EORTC LATE RADIATION MORBIDITY 
TISSUES GRADE 1 GRADE 2 GRADE 3 GRADE 4 
Skin Slight atrophy; 
pigmentation 
change; some 
hair loss 
Patchy 
atrophy; 
moderate 
telangiectasia; 
hair loss 
Marked 
atrophy; gross 
telangiectasia 
Ulceration 
Mucous 
membrane 
Slight  atrophy 
and dryness 
Moderate 
atrophy and 
telangiectasia; 
little mucous 
Marked 
atrophy with 
complete 
dryness 
Ulceration 
Salivary 
glands 
Slight dryness 
of mouth; 
good response 
of stimulation 
Moderate 
dryness of 
mouth; poor 
response on 
stimulation 
Complete 
dryness of 
mouth; no 
response to 
stimulation 
Fibrosis 
Pharynx &  
Oesophagus 
Mild fibrosis; 
slight 
difficulty in 
swallowing 
solids; no pain 
on swallowing 
Unable to take 
solid food 
normally; 
swallowing 
semisolid food; 
dilatation may 
be indicated 
Severe 
fibrosis; able 
to swallow 
only liquids; 
may have pain 
on swallowing 
Necrosis/ 
perforation fistula 
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                     GRADING OF  TOXICITY PROFILES: 
 
 
 
STATISTICS TO BE USED: 
SPSS for Windows 13.0 (Statistical Package for the Social Sciences, Chicago, 
IL). 
The statistics used include ANOVA, Turkey HSD and Post Hoc methods. 
DETAILED BUDGET PLAN: 
Rs. 10,000. 
 
 
CLINICAL 
CHARACTERISTICS 
POST RT 90 DAYS POST 
RT 
MUCOSITIS   
SKIN  REACTIONS   
DYSPHAGIA   
XEROSTOMIA   
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Fig 8 : Armamentarium for Clinical Examination 
 
Fig  :Graduated saliva container  
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Fig 11 : Patient with OSCC 
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                                                  RESULTS 
           The present study was conducted to compare the toxicity profiles in 
head and neck cancer patients undergoing 3D CRT, IMRT and IGRT modes of 
radiotherapy between January 2017 to November 2017. The results are 
tabulated and described as follows   
TABLE 1: INCIDENCE OF MUCOSITIS POST RT IN 3D CRT, IMRT    
 AND IGRT GROUP OF PATIENTS: 
       Among the 20 ( 100%) patients in 3D CRT group, 6 (30%) had grade 2 
mucositis, and 14(70%) had grade 3 mucositis. Among the 20(100%) patients 
in IMRT group, 2(10%) had grade 1 mucositis and 18 (90%) had grade 2 
mucositis. Among the 20 (100%) patients in IGRT group, 3(15%) had grade 1 
mucositis and 17(85%) had grade 2 mucositis. 
TABLE 2: COMPARISON OF MUCOSITIS POST RT IN 3D CRT AND   
IMRT GROUPS: 
       On comparing the grades of mucositis between 3D CRT and IMRT 
groups, out of the 20 patients in 3D CRT group 6(30%) had grade 2 mucositis 
and 14(70%) had grade 3 mucositis and out of the 20 patients in IMRT  group 
2 (10%) had grade 1 mucositis and 18(90%) had grade 2 mucositis. The P 
value was found to be 0.000 which was statistically significant.  
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TABLE 3: COMPARISON OF MUCOSITIS POST RT IN 3D CRT AND 
IGRT GROUPS: 
       On comparing the grades of mucositis between 3D CRT and IGRT 
groups, out of the 20 patiemts in 3D CRT group 6 (30%) had grade 2 
mucositis and 14 (70%) had grade 3 mucositis and out of the 20 patients in 
IGRT group 3(15%) had grade 1 mucositis and 17(85%) had grade 2 
mucositis. . The  P value was found to be 0.000 which was statistically 
significant.  
TABLE 4: COMPARISON OF MUCOSITIS POST RT IN IMRT AND IGRT 
GROUP OF PATIENTS: 
          On comparing the grades of mucositis between IMRT and IGRT groups, 
out of the 20 patients in IMRT group, 2 (10%) had grade 1 mucositis, amd 
18(90%) had grade 2 mucositis. The P value was found to be 0.912 which was 
statistically insignificant. 
TABLE 5: INCIDENCE OF MUCOSITIS 90 DAYS POST RT IN 3D CRT, 
IMRT AND IGRT GROUP OF PATIENTS: 
       Among the 20 (100%) of patients in 3D CRT group, 10 (50%) had grade 1 
mucositis ,10 (50%) had grade 2 mucositis. Among the 20 patients in IMRT 
group, 16 (80%) had grade 1 mucositis, 4 (20%) had grade 2 mucositis. 
Among the 20 patients in IGRT group, 18(90%) had grade 1 mucositis  and 2 
(10%) had grade 2 mucositis. 
                                                                                    Results 
 
64 
 
TABLE 6: COMPARISON OF MUCOSITIS 90 DAYS POST RT IN 3D CRT 
AND IMRT GROUPS: 
          On comparing the grades of mucositis between 3D CRT and IMRT 
groups, out of the 20 patients, in 3D CRT group, 10 (50%) had grade 1 
mucositis, 10 (50%) had grade 2 mucositis  and out of the 20 patients in the 
IMRT group, 16(80%) had grade I mucositis and 4(20%) had grade 2 
mucositis. The P value was found to be 0.069 which was statistically 
significant. 
TABLE 7: COMPARISON OF MUCOSITIS 90 DAYS POST RT IN 3D CRT 
AND IGRT GROUPS: 
       On comparing the grades of  mucositis between 3D CRT and IGRT 
groups, out of the 20 patients , in 3D CRT group, 10 (50%) had grade 1 
mucositis, 10 50%) had grade 2 mucositis and out of the 20 patients in the 
IGRT group, 18(90%) had grade1 mucositis and 2(10%) had grade 2 
mucositis. The P value was found to be 0.010 which was staristically 
significant. 
TABLE 8: COMPARISON OF MUCOSITIS 90 DAYS POST RT 
BETWEEN IMRT AND IGRT GROUPS: 
      On comparing the grades of mucositis  between IMRT and IGRT groups, 
out of the 20 patients in IMRT  group, 16(80%) had grade 1 mucositis and 4 
(20%) had grade 2 mucositis and out of the 20 patients in IGRT group 18 
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(90%) had grade 1 mucositis and 2 (10%) had grade 2 mucositis. The P value 
was found to be 0.732 which was statistically insignificant. 
TABLE 9: INCIDENCE OF SKIN REACTIONS POST RT IN 3D CRT, 
IMRT AND IGRT GROUPS OF PATIENTS: 
         Among the 20 (100%) of patients in 3D CRT group 13 (65%) had grade 
1skin reactions, 5 (25%) had  grade 2 skin reactions  and 2 (10%) had grade 3 
skin reactions. Among the 20 (100%) of patients in the IMRT group, 18(90%) 
had grade 1 skin reactions and 2(10%) had grade2 skin reactions. Among the 
20 (100%) of patients in the IGRT group, 18(90%) had grade 1 skin reactions 
and 2(10%) had grade2 skin reactions. 
TABLE 10: COMPARISON OF SKIN REACTIONS POST RT IN 3D CRT, 
IMRT GROUPS: 
          On comparing the grades of skin reactions , between 3D CRT and IMRT 
groups, out of the 20 patients in 3D CRT group 13(65%) had grade 1 skin 
reactions,  5 (25%) had grade 2 skin reactions and out of the 20 patients  in 
IMRT group, 18(90%) had grade 1 skin reactions, and 2 (10%) had grade 2 
skin reactions. The P value was found to be 0.004 which was statistically 
significant. 
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TABLE 11: COMPARISON OF SKIN REACTIONS POST RT IN 3D CRT 
AND IGRT GROUPS: 
        On comparing the grades of skin reactions, between 3D CRT and IGRT 
groups, out of the 20 patients in the 3D CRT group 13(65%) have grade 1 skin 
reactions, 5(25%) have grade 2 skin reactions and out of the 20 patients in  
IGRT group 18(90%) have grade 1 skin reactions and 2(10%) have grade 2 
skin reactions. The P value was found to be 0.002 which was statistically 
significant. 
TABLE 12: COMPARISON OF SKIN REACTIONS POST RT IN IMRT 
AND IGRT GROUPS: 
        On comparing the grades of skin reactions, between IMRT and IGRT 
groups, out of the 20 patients in the IMRT group 18(90%) had grade 1 skin 
reactions , 2 (10%) had grade 2 skin reactions and out of the 20 patients in 
IGRT group, 18(90%) have grade 1 skin reactions and 2(10%) have grade 2 
skin reactions. The P value was found to be 0.969 which was not statistically 
insignificant.  
 TABLE 13: INCIDENCE OF SKIN REACTIONS 90 DAYS POST RT IN 
3D CRT, IMRT AND IGRT GROUPS: 
        Among the 20 (100%) patients in 3D CRT group, 17(85%) had grade 1 
skin reactions and 3(15%) had grade 2 skin reactions. Among the 20 (100%)of 
patients in the IMRT group, 11(55%) had grade 1 skin reactions, 2 (10%) had 
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grade 2 skin reactions. Among the 20 (100%) of patients in the IGRT group, 
10 (50%) had grade 1 skin reactions and 3(15%) had grade 2 skin reactions. 
TABLE 14: COMPARISON OF SKIN REACTIONS 90 DAYS POST RT IN 
3D CRT, IMRT GROUPS: 
        On comparing the grades of skin reactions between 3D CRT and IMRT 
groups, out of the 20 patients in 3D CRT group  17 (85%) had grade 1 skin 
reactions and 3(15%) had grade 2 skin reactions and out of the 20 patients in 
IMRT group, 11(55%) had grade 1 skin reactions and 2 (10%)had grade 2 skin 
reactions. The P value was found to be 0.000 which was statistically 
significant.  
TABLE 15: COMPARISON OF SKIN REACTIONS 90 DAYS POST T IN 
3D CRT , IGRT GROUPS: 
         On comparing the grades of skin reactions between 3D CRT and IGRT 
groups, out of the 20 patients in 3D CRT group  17 (85%) had grade 1 skin 
reactions and 3(15%) had grade 2 skin reactions and out of the 20 patients in 
IGRT group, 10(50%) had grade 1 skin reactions and 3 (15%)had grade 2 skin 
reactions. The P value was found to be 0.000 which was statistically 
significant.  
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TABLE 16: COMPARISON  OF SKIN REACTIONS 90 DAYS POST RT IN 
IMRT AND IGRT GROUPS: 
         On comparing the grades of skin reactions between IMRT and IGRT 
groups, out of the 20 patients in IMRT group  11 (55%) had grade 1 skin 
reactions and 2(10%) had grade 2 skin reactions and out of the 20 patients in 
IGRT group, 10(50%) had grade 1 skin reactions and 3 (15%)had grade 2 skin 
reactions. The P value was found to be 0.679 which was not  statistically 
significant.  
 TABLE 17: INCIDENCE OF XEROSTOMIA POST RT IN 3D CRT, IMRT 
AND IGRT GROUPS: 
Among the 20 (100%) of patients in the 3D CRT group, 15(75%) had grade 1 
xerostomia, 3 (15%) had grade 2 xerostomia. Among the 20(100%) of patients 
in the IMRT group, 13(65%) had grade I xerostomia, 3(15%) had grade 2 
xerostomia. Among the 20 (100%) in the IGRT group, 14(70%) had grade 1 
xerostomia and 3(15%) had grade 2 xerostomia. 
TABLE 18: COMPARISON OF XEROSTOMIA POST RT IN 3D CT, IMRT 
GROUPS: 
On comparing the grades of xerostomia between 3D CRT and IMRT groups, 
out of the 20 patients in 3D CRT group, 15(75%) had grade 1 xerostomia, 
3(15%) had grade 2 xerostomia and out of the 20 patients in the IMRT group, 
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13(65%) had grade 1 xerostomia and 3 (15%) had grade 2 xerostomia. The P 
value was found to be 1.000 which was not statistically significant. 
TABLE 19: COMPARISON OF XEROSTOMIA POST RT IN 3D CRT, 
IGRT GROUPS: 
On comparing the grades of xerostomia between 3D CRT and IGRT groups, 
out of the 20 patients in 3D CRT group, 15(75%) had grade 1 xerostomia, 
3(15%) had grade 2 xerostomia and out of the 20 patients in the IGRT group, 
14(70%) had grade 1 xerostomia and 3 (15%) had grade 2 xerostomia. The P 
value was found to be 0.532  which was not statistically significant. 
TABLE 20: COMPARISON OF XEROSTOMIA POST RT IN IMRT AND 
IGRT GROUPS: 
On comparing the grades of xerostomia between IMRT and IGRT groups, out 
of the 20 patients in IMRT  group, 13(65%) had grade 1 xerostomia, 3(15%) 
had grade 2 xerostomia and out of the 20 patients in the IGRT group, 14(70%) 
had grade 1 xerostomia and 3 (15%) had grade 2 xerostomia. The P value was 
found to be 0.532  which was not statistically significant. 
TABLE 21: INCIDENCE  OF XEROSTOMIA 90 DAYS POST RT IN 
3DCRT, IMRT AND IGRT GROUPS: 
Among the 20 (100%) of patients in the 3D CRT group, 15(75%) had grade 1 
xerostomia, 5 (25%) had grade 2 xerostomia. Among the 20(100%) of patients 
in the IMRT group, 17(85%) had grade I xerostomia, 2(10%) had grade 2 
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xerostomia. Among the 20 (100%) in the IGRT group, 16(80%) had grade 1 
xerostomia and 1(5%) had grade 2 xerostomia. 
TABLE 22: COMPARISON OF XEROSTOMIA 90 DAYS POST RT IN 3D 
CRT AND IMRT GROUPS: 
On comparing the grades of xerostomia   between 3D CRT  and IMRT groups, 
out of the 20 patients in 3D CRT  group, 15(75%) had grade 1 xerostomia, 
5(25%) had grade 2 xerostomia and out of the 20 patients in the IMRT group, 
17(85%) had grade 1 xerostomia and 2 (10%) had grade 2 xerostomia. The P 
value was found to be 0.000  which was statistically significant. 
TABLE 23: COMPARISON OF XEROSTOMIA 90 DAYS POST RT IN 3D 
CRT AND IGRT GROUPS: 
On comparing the grades of xerostomia  between 3D CRT  and IGRT groups, 
out of the 20 patients in 3D CRT  group, 15(75%) had grade 1 xerostomia, 
5(25%) had grade 2 xerostomia and out of the 20 patients in the IGRT group, 
16(80%) had grade 1 xerostomia and 1 (5%) had grade 2 xerostomia. The P 
value was found to be 0.000  which was statistically significant 
TABLE 24: COMPARISON OF XEROSTOMIA 90 DAYS POST RT IN 
IMRT AND IGRT GROUPS: 
On comparing the grades of xerostomia   between IMRT   and IGRT groups, 
out of the 20 patients in IMRT   group, 17(85%) had grade 1 xerostomia, 
2(10%) had grade 2 xerostomia and out of the 20 patients in the IGRT group, 
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16(80%) had grade 1 xerostomia and 1 (5%) had grade 2 xerostomia. The P 
value was found to be 0.497  which was not statistically significant. 
TABLE 25: INCIDENCE  OF DYSPHAGIA POST RT IN 3D CRT, IMRT 
AND IGRT GROUPS: 
Among the 20 (100%) of patients in the 3D CRT group, 11(55%) had grade 1 
dysphagia, 7 (35%) had grade 2 dysphagia and 2(10%) had grade 3 dysphagia 
. Among the 20(100%) of patients in the IMRT group, 19(95%) had grade I 
dysphagia, 1(5%) had grade 2 dysphagia. Among the 20 (100%) in the IGRT 
group, 19(95%) had grade 1 dysphagia and 1(5%) had grade 2 dysphagia. 
TABLE 26: COMPARISON OF DYSPHAGIA POST RT IN 3D CRT AND 
IMRT GROUPS: 
On comparing the grades of dysphagia  between 3D CRT  and IMRT groups, 
out of the 20 patients in 3D CRT  group, 11(55%) had grade 1 dysphagia, 
7(35%) had grade 2 dysphagia  2(10%) had grade 3 dysphagia and out of the 
20 patients in the IMRT group, 19(95%) had grade 1 dysphagia and 1 (5%) 
had grade 2 dysphagia. The P value was found to be 0.000  which was 
statistically significant. 
TABLE 27: COMPARISON OF DYSPHAGIA POST RT IN 3D CRT AND 
IGRT GROUPS: 
On comparing the grades of dysphagia  between 3D CRT  and IGRT groups, 
out of the 20 patients in 3D CRT  group, 11(55%) had grade 1 dysphagia 
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7(35%) had grade 2 dysphagia  2(10%) had grade 3 dysphagia and out of the 
20 patients in the IGRT group, 19(95%) had grade 1 dysphagia and 1 (5%) had 
grade 2 dysphagia. The P value was found to be 0.000  which was statistically 
significant. 
TABLE 28: COMPARISON OF DYSPHAGIA POST RT IN IMRT AND 
IGRT GROUPS: 
On comparing the grades of dysphagia  between IMRT  and IGRT groups, out 
of the 20 patients in IMRT  group, 19(95%) had grade 1 dysphagia, 1(5%) had 
grade 2 dysphagia   and out of the 20 patients in the IGRT group, 19(95%) had 
grade 1 dysphagia and 1 (5%) had grade 2 dysphagia. The P value was found 
to be 0.966  which was statistically not significant. 
TABLE 29: INCIDENCE OF  DYSPHAGIA 90 DAYS POST RT IN 3D 
CRT, IMRT AND IGRT GROUPS: 
Among the 20 (100%) of patients in the 3D CRT group, 13(65%) had grade 1 
dysphagia, 7 (35%) had grade 2 dysphagia . Among the 20(100%) of patients 
in the IMRT group, 10(50%) had grade I dysphagia, 1(5%) had grade 2 
dysphagia. Among the 20 (100%) in the IGRT group, 9(45%) had grade 1 
dysphagia and 3(15%) had grade 2 dysphagia. 
TABLE 30: COMPARISON OF DYSPHAGIA 90 DAYS POST RT IN 3D 
CRT AND IMRT GROUPS: 
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On comparing the grades of dysphagia  between 3D CRT  and IMRT groups, 
out of the 20 patients in 3D CRT  group, 13(65%) had grade 1 dysphagia, 
7(35%) had grade 2 dysphagia and   in the IMRT group, 10(50%) had grade 1 
dysphagia and 1 (5%) had grade 2 dysphagia. The P value was found to be 
0.001  which was statistically significant. 
TABLE 31: COMPARISON OF DYSPHAGIA 90 DAYS POST RT IN 3D 
CT AND IGRT GROUPS: 
On comparing the grades of dysphagia  between 3D CRT  and IGRT groups, 
out of the 20 patients in 3D CRT  group, 13(65%) had grade 1 dysphagia, 
7(35%) had grade 2 dysphagia and   in the IMRT group, 9(45%) had grade 1 
dysphagia and 3 (15%) had grade 2 dysphagia. The P value was found to be 
0.000  which was statistically significant. 
TABLE 32: COMPARISON OF DYSPHAGIA 90 DAYS POST RT IN IMRT 
AND IGRT GROUPS: 
On comparing the grades of dysphagia  between IMRT  and IGRT groups, out 
of the 20 patients in IMRT  group, 10(50%) had grade 1 dysphagia 1(5%) had 
grade 2 dysphagia and   in the IGRT group, 9(45%) had grade 1 dysphagia and 
3 (15%) had grade 2 dysphagia. The P value was found to be 0.903  which was 
not  statistically significant 
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TABLE 1:INCIDENCE OF MUCOSITIS POST RT IN 3D CRT , IMRT AND IGRT PATIENTS 
Mucositis 
grade 
 
3D CRT % IMRT % IGRT % 
 1 - - 2 10% 3 15% 
 2 6 30% 18 90% 17 85% 
 3 14 70% - - - - 
 4 - - - - - - 
Total 20 100% 20 100% 20 100% 
 
TABLE 2:COMPARISON OF MUCOSITIS POST RT AMONG 3DCRT AND IMRT 
Mucositis 
grade 
3D CRT % IMRT % P VALUE 
 1  - - 2 10%  
0.000 2 6 30% 18 90% 
 3 14 70%  -  - 
 4 - - - - 
Total 20 100% 20 100%  
 
TABLE 3: COMPARISON OF  MUCOSITIS POST RT AMONG 3D CRT AND IGRT 
Mucositis 
grade 
3D CRT % IGRT % P VALUE 
 1 -  - 3 15%  
0.000  2 6 30% 17 85% 
 3 14 70% -  - 
4 - - -  - 
Total 20 100% 20 100%  
 
TABLE 4: COMPARISON  OF  MUCOSITIS POST RT AMONG IMRT AND IGRT 
Mucositis 
grade 
IMRT % IGRT % P VALUE 
 1 2 10% 3 15%  
.912  2 18 90% 17 85% 
 3 - - - - 
 4 - - - - 
Total 20 100% 20 100%  
 
 
 
 
 
                                                                                                  Tables & Graphs 
 
75 
 
 
 
TABLE 5: INCIDENCE OF MUCOSITIS 90 DAYS POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
Mucositis 
grade 
3D CRT  % IMRT % IGRT % 
1 10 50% 16 80% 18 90% 
2 10 50% 4 20% 2 10% 
3 - - - - - - 
4 - - - - - - 
Total 20 100% 20 100% 20 100% 
 
TABLE 6:COMPARISON OF MUCOSITIS 90 FDAYS POST RT IN 3D CRT AND IMRT GROUPS: 
Mucositis 
grade 
3D CRT % IMRT % P VALUE 
1 10 50% 16 80%  
.069 2 10 50% 4 20% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 7:COMPARISON OF MUCOSITIS 90 DAYS POST RT IN 3D CRT AND IGRT GROUPS: 
Mucositis 
grade 
3D CRT % IGRT % P VALUE 
1 10 50% 18 90% .010 
2 10 50% 2 10% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 8: COMPARISON OF MUCOSITIS 90 DAYS IN POST RT IN  IMRT AND IGRT GROUPS: 
Mucositis 
grade 
IMRT % IGRT % P VALUE 
1 16 80% 18 90% .732 
2 4 20% 2 10% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
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TABLE 9: INCIDENCE OF SKIN REACTIONS POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
Skin 
reactions 
grade 
3D CRT  % IMRT % IGRT % 
1 13 65% 18 90% 18 90% 
2 5 25% 2 10% 2 10% 
3 2 10% - - - - 
4 - - - - - - 
Total 20 100% 20 100% 20 100% 
 
TABLE 10: COMPARISON OF SKIN REACTIONS POST RT IN 3D CRT AND IMRT GROUPS: 
Skin reactions 
grade 
3D CRT % IMRT % P VALUE 
1 13 65% 18 90%  
.004 2 5 25% 2 10% 
3 2 10% - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 11: COMPARISON OF SKIN REACTIONS POST RT IN 3D CRT AND IGRT GROUPS: 
Skin reactions 
grade 
3D CRT  % IGRT % P VALUE 
1 13 65% 18 90%  
0.002 2 5 25% 2 10% 
3 2 10% - - 
4 - - - - 
Total  20 100% 20 100%  
 
TABLE 12: COMPARISON OF SKIN REACTIONS POST RT IN IMRT AND IGRT GROUPS: 
Skin reactions 
grade 
IMRT % IGRT % P VALUE 
1 18 90% 18 90%  
.969 2 2 10% 2 10% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
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TABLE 13: INCIDENCE  OF SKIN REACTIONS 90 DAYS  POST RT IN 3D CRT, IMRT, IGRT GROUPS: 
Skin 
reactions 
grade 
3D CRT  % IMRT % IGRT % 
1 17 85% 11 55% 10 50% 
2 3 15% 2 10% 3 15% 
3 - - - - - - 
4 - - - - - - 
Total 20 100% 20 100% 20 100% 
 
TABLE 14: COMPARISON OF SKIN REACTIONS 90 DAYS POST RT IN 3D CRT AND IMRT GROUPS: 
Skin reactions 
grade 
3D CRT % IMRT % P VALUE 
1 17 85% 11 55%  
0.000 2 3 15% 2 10% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 15: COMPARISON OF SKIN REACTIONS 90 DAYS POST RT IN 3D CRT AND IGRT GROUPS: 
Skin reactions 
grade 
3D CRT % IGRT % P VALUE 
1 17 85% 10 50%  
0.000 2 3 15% 3 15% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 16: COMPARISON OF SKIN REACTIONS 90 DAYS POST RT IN IMRT AND IGRT GROUPS: 
Skin reactions 
grade 
IMRT % IGRT % P VALUE 
1 11 55% 10 50%  
0.679 2 2 10% 3 15% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
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TABLE 17: INCIDENCE OF XEROSTOMIA POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
Xerostomia 
grade 
3D CRT % IMRT % IGRT % 
1 15 75% 13 65% 14 70% 
2 3 15% 3 15% 3 15% 
3 - - - - - - 
4 - - - - - - 
Total 20 100% 20 100% 20 100% 
 
TABLE 18: COMPARISON OF XEROSTOMIA POST RT IN 3D CRT AND IMRT GROUPS: 
Xerostomia 
grade 
3D CRT  % IMRT % P VALUE 
1 15 75% 13 65%  
1.000 2 3 15% 3 15% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 19: COMPARISON OF XEROSTOMIA POST RT IN 3D CRT AND IGRT GROUPS: 
Xerostomia 
grade 
3D CRT % IGRT  P VALUE 
1 15 75% 14 70%  
.532 2 3 15% 3 15% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 20: COMPARISON OF XEROSTOMIA POST RT IN IMRT AND IGRT GROUPS: 
Xerostomia 
grade 
IMRT % IGRT % P VALUE 
1 13 65% 14 70%  
.532 2 3 15% 3 15% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
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TABLE 21: INCIDENCE OF XEROSTOMIA 90 DAYS POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
Xerostomia 
grade 
3D CRT % IMRT % IGRT % 
1 15 75% 17 85% 16 80% 
2 5 25% 2 10% 1 5% 
3 - - - - - - 
4 - - - - - - 
Total 20 100% 20 100% 20 100% 
 
TABLE 22: COMPARISON OF XEROSTOMIA 90 DAYS IN 3D CRT AND  IMRT GROUPS 
Xerostomia 
grade  
3D CRT % IMRT % P VALUE 
1 15 75% 17 85%  
0.000 2 5 25% 2 10% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 23: COMPARISON OF XEROSTOMIA 90 DAYS POST RT IN 3D CRT AND IGRT GROUPS: 
Xerostomia 
grade 
3D CRT % IGRT  P VALUE 
1 15 75% 16 80%  
0.000 2 5 25% 1 5% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 24: COMPARISON OF XEROSTOMIA 90 DAYS POST RT IN IMRT AND IGRT GROUPS: 
Xerstomia 
grade 
IMRT % IGRT % P VALUE 
1 17 85% 16 80%  
0.497 2 2 10% 1 5% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
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TABLE 25: INCIDENCE OF DYSPHAGIA POST RT IN 3D CRT, IMRT  AND IGRT GROUPS: 
Dysphagia 
grade 
3D CRT % IMRT % IGRT % 
1 11 55% 19 95% 19 95% 
2 7 35% 1 5% 1 5% 
3 2 10% - - - - 
4 - - - - - - 
Total 20 100% 20 100% 20 100% 
  
TABLE 26: COMPARISON OF DYSPHAGIA POST RT IN 3D CRT AND IMRT GROUPS: 
Dysphagia 
grade 
3D CRT % IMRT % P VALUE 
1 11 55% 19 95%  
 
0.000 
2 7 35% 1 5% 
3 2 10% - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 27: COMPARISON OF DYSPHAGIA POST RT IN 3D CRT AND IGRT GROUPS: 
Dysphagia 
grade 
3D CRT % IGRT % P VALUE 
1 11 55% 19 95%  
 
0.000 
2 7 35% 1 5% 
3 2 10% - _ 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 28: COMPARISON OF DYSPHAGIA POST RT IN IMRT AND IGRT GROUPS: 
Dysphagia 
grade 
IMRT % IGRT % P VALUE 
1 19 95% 19 95%  
 
0.966 
2 1 5% 1 5% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
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TABLE 29: INCIDENCE OF DYSPHAGIA 90 DAYS POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
Dysphagia 
grade 
3D CRT % IMRT % IGRT % 
1 13 65% 10 50% 9 45% 
2 7 35% 1 5% 3 15% 
3 - - - - - - 
4 - - - - - - 
Total 20 100% 20 100% 20 100% 
 
TABLE 30: COMPARISON OF DYSPHAGIA 90 DAYS POST RT IN 3D CRT  AND IMRT GROUPS: 
Dysphagia 
grade 
3D CRT % IMRT % P VALUE 
1 13 65% 10 50%  
0.001 2 7 35% 1 5% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
 
TABLE 31: COMPARISON OF DYSPHAGIA 90 DAYS POST RT IN 3D CRT AND IGRT GROUPS: 
Dysphagia 
grade 
3D CRT % IGRT % P VALUE 
1 13 65% 9 45%  
 
0.000 
2 7 35% 3 15% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100% 
 
TABLE 32: COMPARISON OF DYSPHAGIA 90 DAYS POST RT IN IMRT AND IGRT GROUPS: 
Dysphagia 
grade 
IMRT % IGRT % P VALUE 
1 10 50% 9 45%  
0.903 2 1 5% 3 15% 
3 - - - - 
4 - - - - 
Total 20 100% 20 100%  
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GRAPH 1: INCIDENCE OF MUCOSITIS POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
 
 
 
GRAPH 2: COMPARISON OF MUCOSITIS POST RT IN 3D CRT AND IMRT GROUPS: 
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GRAPH 3: COMPARISON OF MUCOSITIS POST RT IN 3D CRT AND IGRT GROUPS: 
 
 
 
GRAPH 4: COMPARISON OF MUCOSITIS POST RT IN IMRT AND IGRT GROUPS: 
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GRAPH 5: INCIDENCE OF MUCOSITIS 90 DAYS  POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
 
 
 
GRAPH 6 : COMPARISON OF MUCOSITIS 90 DAYS POST RT IN 3D CRT AND IMRT GROUPS:  
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GRAPH 7: COMPARISON OF MUCOSITIS 90 DAYS POST RT IN 3D CRT AND IGRT GROUPS: 
 
 
 
 
GRAPH  8: COMPARISON OF MUCOSITIS 90 DAYS POST RT IN IMRT AND IGRT GROUPS: 
 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
GRADE 1 GRADE 2 GRADE 3 GRADE 4
3D CRT
IGRT
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
GRADE 1 GRADE 2 GRADE 3 GRADE 4
IMRT
IGRT
                                                                                                  Tables & Graphs 
 
86 
 
 
GRAPH 9:  INCIDENCE OF SKIN REACTIONS POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
 
 
 
GRAPH 10: COMPARISON OF SKIN REACTIONS POST RT IN 3D CRT AND IMRT GROUPS: 
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GRAPH 11: COMPARISON OF SKIN REACTIONS POST RT IN 3D CRT AND IGRT GROUPS: 
 
 
GRAPH 12: COMPARISON OF SKIN REACTIONS POST RT IN IMRT AND IGRT GROUPS: 
 
 
 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
GRADE 1 GRADE 2 GRADE 3 GRADE 4
3D CRT
IGRT
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
GRADE 1 GRADE 2 GRADE 3 GRADE  4
IMRT
IGRT
                                                                                                  Tables & Graphs 
 
88 
 
GRAPH 13: INCIDENCE OF SKIN REACTIONS90 DAYS POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
 
 
 
GRAPH 14: COMPARISON OF SKIN REACTIONS 90 DAYS POST RT IN 3D CRT AND IMRT GROUPS: 
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GRAPH 15: COMPARISON OF SKIN REACTIONS 90 DAYS POST RT IN 3D CRT AND IGRT GROUPS: 
 
 
GRAPH 16 : COMPARISON OF SKIN REACTIONS 90 DAYS POST RT IN IMRT AND IGRT GROUPS: 
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GRAPH 17: INCIDENCE OF XEROSTOMIA POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
 
 
 
GRAPH 18: COMPARISON OF XEROSTOMIA POST RT IN 3D CRT, IMRT GROUPS: 
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GPAPH 19: COMPARISON OF XEROSTOMIA  POST RT IN 3D CRT AND IGRT GROUPS: 
 
 
GRAPH 20 : COMPARISON OF XEROSTOMIA  POST RT IN IMRT AND IGRT GROUPS: 
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GRAPH  21: INCIDENCE OF  XEROSTOMIA 90 DAYS POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
 
 
GRAPH 22: COMPARISON OF XEROSTOMIA 90 DAYS POST RT IN 3D CRT, IMRT AND GROUPS: 
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GRAPH  23: COMPARISON OF XEROSTOMIA 90 DAYS POST RT IN 3D CRT AND IGRT GROUPS: 
 
 
 
GRAPH 24: COMPARISON OF XEROSTOMIA 90 DAYS POST RT IN IMRT AND IGRT GROUPS: 
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GRAPH 25: INCIDENCE OF DYSPHAGIA POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
 
 
GRAPH 26: COMPARISON OF DYSPHAGIA POST RT IN 3D CRT AND IMRT GROUPS: 
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GRAPH 27: COMPARISON OF DYSPHAGIA POST RT IN 3D CRT AND IGRT GROUPS: 
 
 
GRAPH 28: COMPARISON OF DYSPHAGIA POST RT IN IMRT AND IGRT GROUPS: 
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GRAPH 29: INCIDENCE OF DYSPHAGIA  90 DAYS POST RT IN 3D CRT, IMRT AND IGRT GROUPS: 
 
 
GRAPH 30: COMPARISON OF DYSPHAGIA 90 DAYS POST RT IN 3D CRT, IMRT   GROUPS: 
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GRAPH 31: COMPARISON OF DYSPHAGIA 90 DAYS POST RT IN 3D CRT AND IGRT GROUPS: 
 
 
 
 
 
GRAPH 32: COMPARISON OF DYSPHAGIA  90 DAYS POST RT IN IMRT AND IGRT GROUPS: 
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                                                     DISCUSSION 
             Among the different modes of treatment of oral cancer radiotherapy  
and chemotherapy remain the key modalities. By combining a 
chemotherapeutic agent with radiation, the efficacy of radiotherapy is 
increased and results in better tumour control and survival rates. Adjuvant 
chemoradiotherapy is used as an effort to completely eradicate advanced 
disease and metastases 
28
 External beam radiotherapy or teletherapy is the 
most frequently used form of radiotherapy. The shape and intensity of the 
electron beam produced by a Linac may be modified or collimated  by a 
variety of means. Thus conventional, conformal, intensity modulated,  
tomographic and stereotactic RT  are all produced by specially modified linear 
accelerators. 
             Conformal radiotherapy aims at an optimal dose distribution, which 
requires a sophisticated planning of radiation treatment. Substantial 
development and impressing improvements in the planning devices have lead 
to the advent of a new modality called 3 dimensional conformal 
radiotherapy ( 3D CRT) 
18
 Here the radiation field conforms to the shape of 
the volume to be treated. To optimize the dose distribution, the clinical target 
volume (CTV) and the normal tissue must be defined with very high accuracy 
by the radiotherapist.  The CTV contains the clinically evident tumour ( Gross 
tumour volume, GTV),  along with a margin of microscopic tumour  spread 
which includes the lymphatics. The CTV has to obtain 100% of the radiation 
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dose with a dose distribution of highest homogeneity. Macroscopic tumour 
masses are detected by CT, MRI and biological activity of the tumour is 
detected by SPECT, PET etc. In order to ensure an optimum of precision and 
reproducibility in dose delivery and dose distribution, the positioning of the 
patient has to be identical during the diagnostic procedures, the process of 
treatment simulation, and the whole radiation treatment. This is achieved by a 
process called immobilization which includes devices like head holders with 
masks, foam molds and evacuated bags, so that the movement of almost any 
anatomical region of a cooperative patient can be reduced to less than 5 mm.  
External markers are placed on the immobilization device or/and the patient to 
delineate the coordinates system. After identical positioning of the target 
volume, the calculation of dose distribution is done. Using the fixation 
devices, and laser system, it is ensured that every point of the coordinates in 
the X-ray, CT or MRI device will be at the same coordinates in each scan of 
the patient. It is possible to study the shape of the different beams in 
comparison to the contour of the tumour by looking along the central axis of 
the beam (beam’s eye view). Using the beam’s eye view, the contour of every 
beam can be designed very close to the tumour border, after which dose 
calculation is performed. To compare different treatment plans on a numerical 
base, integrated dose-volume histograms (DVH) are used. The final procedure 
is the simulation and treatment procedure which includes the verification of 
the calculated plan by X-ray control. Following all the procedural steps 
carefully, a  highly precise radiation dose is delivered.
18
 However the radiation 
                                                                                    Discussion 
 
100 
 
intensity is uniform within each beam and the modulation is conferred only by 
wedges. Hence in order to further improve the therapeutic ratio ,to reduce the 
dose to the neighbouring normal tissues , and to achieve a better locoregional 
control there arose a need for the advent of a more conformal form of 
radiotherapy.   
         The advent of intensity modulated radiotherapy ( IMRT), has ushered 
in a new paradigm that has completely revolutionized contemporary 
radiotherapy practice. This is a highly précised  form of radiotherapy, 
delivering radiation beams with  more than two intensity levels, from a single 
beam direction and a single source of position in space. It excludes beams that 
use a transmission block with a single attenuation level, standard dynamic or 
static wedges, single boost field inside the main field, as well as beams used in 
conformal arc therapy. The promise of generating highly conformal and 
concave dose distributions around complex target volumes with steep dose 
gradients makes IMRT ideally suited to Head and Neck Cancer. The  heart of 
the process is a concept called inverse treatment planning in which the clinical 
objectives are specified mathematically and a computer optimization 
algorithm is used to automatically determine beam parameters (mainly 
beamlet weights) that will lead to the desired dose distribution.  Optimization 
is an iterative process that balances the trade-off between target dose and 
coverage versus minimization of impact on normal tissues utilization a cost or 
objective function. The cost function is a mathematical description of criteria 
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of treatment plan optimization (i.e. clinical objectives) and may be specified in 
terms of dose-limits, dose-volume limits, dose-response functions, or other 
formulations.
 
 
                Figure 1:Intensity Modulated Radiotherapy Process  Chain  
 
          The overall accuracy of IMRT depends upon mechanical isocentric 
accuracy of the delivery unit (gantry, collimator, couch), beam stability (at low 
monitor units and small filed sizes), multi-leaf collimator (MLC) system (leaf-
travel and position accuracy, reproducibility) and its characterization into the 
treatment planning system (MLC leaf-end and side leakage, tongue-and-
groove effect, penumbra modeling). Well-defined guidelines for tolerance 
limits and action levels pertaining to various aspects of IMRT dosimetry 
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including a credentialing mechanism has been proposed to ensure that what is 
planned is actually delivered.
25 
           Image guided radiotherapy (IGRT) represents a logical advancement in 
the field of high precision radiotherapy and is a natural corollary to IMRT.
25
 
Some linacs have an on board Imager, an automated system that uses a high 
resolution X rays to produce contrasting images of  cancerous tumours and 
surrounding soft tissue, allowing physicians to target the cancerous tumour 
more precisely during treatment and decreasing radiation exposure if healthy 
tissues. Before the on-board imager, physicians would have to treat a larger 
area of the body near the cancerous tumour to compensate for any tumour 
movement, exposing healthy tissue to the radiation. This technique is called 
image guided radiotherapy (IGRT) . The imaging equipment can also be kept 
inside the treatment room separately (CT on rail) to acquire the scans in the 
treatment position. Thus IMRT improves the radiation delivery precision  by 
using multiple beam angles and giving distinct dose to each segment  and 
IGRT improves the radiation delivery accuracy; thereby decreasing the 
volume of normal tissue being irradiated.
37 
         Though radiation delivery methods and beam shaping has evolved 
continuously with novel methods, it is not without some pitfalls, the most 
important being acute and chronic toxicities that develop after radiotherapy. 
Toxicities that develop within 90 days from the beginning of radiotherapy are 
acute and that developing after 90 days are  chronic. The most common acute 
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side effects are mucositis, skin reactions, dysphagia and  xerostomia. The 
chronic toxicities that develop include  difficulty in mouth opening due to 
fibrosis.
20
 Thus acute and late toxicities of radiotherapy in cancer patients 
represent important clinical outcomes that can substantially reduce quality of 
life and the ability of individuals to complete the entire planned course of 
treatment. 
           Hence this has formed the basis of our study where  we have explored 
the   acute and chronic toxicity profiles associated with  3DCRT, IMRT and 
IGRT in oral cancer patients  which would help us to further optimize the 
process and incorporate re planning strategies to obtain a even better 
locoregional control and thus produce a potential positive impact on the 
quality of life of the patient. 
COMPARISON OF MUCOSITIS POST RT BETWEEN 3D CRT Vs 
IMRT and 3D CRT Vs IGRT GROUPS:  
           On comparing the mucositis occurring  post RT between 3D CRT, 
IMRT and IGRT groups, among the 20 patients  in the 3D CRT group 30% 
had grade 2 mucositis and 70%  had grade 3 mucositis , among the 20 patients 
in the in the IMRT group 10% had grade 1 mucositis and 90% had grade 2 
mucositis and aming the 20 patients in the IGRT group 15% had grade 1 
mucositis and 85% had grade 3 mucositis .The P value is statistically highly 
significant  between 3D CRT and IMRT groups ( 0.000) , and 3D CRT and 
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IGRT groups ( 0.000) and statistically insignificant between IMRT and IGRT 
( 0.912).   
        The results of our study are in accordance with the results of the studies 
conducted by Vergeer  et al( 2009)
62
, Micheal J Spitto et al ( 2014)
42
  Gopa 
Gosh et al ( 2016)
20
, and Ajay Singh Choudhary et al ( 2017)
1
.  
        Vergeer et al (2009)
62
 performed a study compare the mucositis grading  
in 91 patients in the IMRT group and 150 patients in the 3D CRT group and 
found there was a significant difference in acute mucositis in favour of IMRT 
in   weeks 3,4,5 and 12 after treatment with a P value ranging from 0.006 to 
0.016 
         Micheal Spitto et al ( 2014)
42
 did a study  to compare the toxicity 
profiles during treatment with 3D CRT, IMRT with SIB and IMRT without  
SIB with a  statistically highly  significant with a P value of <0.001 in favour 
of IMRT with or without SIB 
        Gopa Gosh et al ( 2016)
20
  conducted  a study  to compare the toxicity 
profiles among 3D CRT and IMRT patients in a sample size of 80 patients , 
out of the 40 patients in the 3D CRT group,  57.5% were found to have grade 
3 mucositis  and out of the 40 patients in the IMRT group,  40% were found to 
have grade 3 mucositis which demonstrated significant results. 
         Ajay Singh Choudhary et al ( 2017)
1
  compared the toxicity profiles 
during treatment of head and neck cancer with 3D CRT and IMRT in a sample 
                                                                                    Discussion 
 
105 
 
size of 150 patients , and found that   significantly higher grade 3 or worse 
mucositis occurred in 57.6% of the 3D CRT group and  39.7% of patients in 
the IMRT group with a P value of 0.03 which was statistically highly 
significant. 
       The results of our study are in contradiction to the results of the studies 
conducted by Gupta et al ( 2012)
24
 and  Tim Kruser et al ( 2013)
59
 . 
       Gupta et al ( 2012)
24
 did a study to compare acute mucositis between 3D 
CRT and  IMRT in a group of 60 patients and found no statistical difference 
between groups, while comparing grade 2 and grade 3 mucositis , but had a 
statistical difference in grade I mucositis.  
         This contradiction may be due to the fact that the site of primary tumour 
also has influence on mucositis. When  a more conformal technique such as 
IMRT is  given to primary tumours located in or near the oral cavity, it might 
result in higher mucositis because of the higher dose given to that region. 
Moreover in their study  a statistical difference was obtained in grade 2 
mucositis.  
          Tim J Kruser et al (2013)
59
 compared  the acute mucositis grading in 
patients undergoing 3D CRT, IMRT and helical tomotherapy  in a sample of 
108  patients, and found  that  the results of the study were not statistically 
significant with a P value of 0.20  in contradiction to the results of our study. 
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COMPARISON OF MUCOSITIS 90 DAYS POST RT IN 3D CRT Vs 
IMRT GROUPS AND 3D CRT Vs IGRT GROUPS:  
         On comparing the grades of mucositis occurring 90 days after RT  
between 3D CRT ,IMRT and IGRT groups,  among  the  of the 20 patients, in 
3D CRT group,  50% had grade 1 mucositis,  50% had grade 2 mucositis  and 
out of the 20 patients in the IMRT group, 80% had grade I mucositis and 20% 
had grade 2 mucositis and among the 20 patients in the IGRT group 90% had 
grade 1 mucositis and 10% had grade 2 mucositis. The P value is statistically 
insignificant between the 3D CRT and IMRT groups (0.069) and statistically 
significant between 3D CRT and IGRT groups (0.010) and statistically 
insignificant between IMRT and IGRT groups ( 0.732). 
         Though statistically insignificant results between the groups of patients 
were obtained  the number of patients affected by grade 2 mucositis  in 3D 
CRT was more when compared to the number of patients in the IMRT group.  
COMPARISON OF SKIN REACTIONS POST RT IN 3D CRT Vs IMRT 
and 3D CRT Vs IGRT GROUPS: 
          On comparing the skin reactions occurring post RT between 3D CRT, 
IMRT and IGRT groups, among  the 20 patients in the 3D CRT group 65% 
had grade 1 skin reactions , 25% had grade 2 reactions  and out of  the 20 
patients in the IMRT group 90% had grade I skin reactions and 10% had grade 
2 skin reactions  and out of  the 20 patients in the IGRT group 90% had grade 
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1 skin reactions and 10% had grade 2 skin reactions. The P value is 
statistically  significant between 3D CRT and IMRT groups ( 0.004) and 
statistically significant between 3D CRT and IGRT groups ( 0.002) and 
statistically insignificant between IMRT and IGRT groups ( 0.969). 
COMPARISON OF SKIN REACTIONS 90 DAYS  POST RT IN 3D CRT 
Vs  IMRT GROUPS AND 3D CRT Vs IGRT GROUPS: 
           On comparing the skin reactions occurring  90 days  post RT between 
3D CRT, IMRT and IGRT groups, among  the 20 patients in the 3D CRT 
group 85% had grade 1 skin reactions , 15% had grade 2 reactions  and out of  
the 20 patients in the IMRT group 55% had grade I skin reactions and 10% 
had grade 2 skin reactions  and out of  the 20 patients in the IGRT group 50% 
had grade 1 skin reactions and 15% had grade 2 skin reactions. The P value is 
statistically highly significant between 3D CRT and IMRT groups ( 0.000) and 
statistically highly  significant between 3D CRT and IGRT groups ( 0.000) 
and statistically insignificant between IMRT and IGRT groups ( 0.679). 
           The results of our study are in accordance with the results of the study 
conducted by Micheal J Spitto et al (2014)
42
  Gopa Gosh et al ( 2016)
20
 . 
 Micheal J Spitto et al ( 2014)
42
,  performed a study to compare the toxicity 
profiles of radiotherapy  in a sample of 379 subjects, out of the 125 patients 
treated with 3D CRT, 44% demonstrated grade 3 or greater dermatitis, out of 
the 120 patients treated with IMRT seq, 20.0% demonstrated grade 3 or 
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greater dermatitis and out of the 134 patients treated with IMRT +SIB, 7.5% 
demonstrated grade 3 or greater dermatitis  and the result were statistically 
highly  significant  with a P value of <0.001.  
         Gopa Gosh et al ( 2016)
20
   compared  the acute and chronic toxicity  in 
a sample of 80 subjects, out of the 40 patients in the 3D CRT group, acute 
grade 3 or greater toxic effects occurred in 5 (12.5%) of the patients and out of 
the 40 patients in the IMRT group, acute grade 3 or greater toxic effects to the 
skin occurred in 3(7.5%) of the patients  which showed a  significant 
difference. 
      The results of our study are not in accordance with the results of the 
studies done by Tejpal Gupta et al (2012)
58
 ,  Ajay Singh Choudhary et al ( 
2017)
1
   
        Tejpal Gupta (2012)
58
 did a study  to compare the toxicity profiles in 
patients with 3D CRT and IMRT modes in a sample of 60, out of the 28 
patients in the 3D CRT group,  14.5% developed grade 3 dermatitis  and out of 
the 32 patients  in the IMRT group , 6% developed grade 3 dermatitis and the 
results of the study were not statistically significant. 
        Though a statistically significant result was not obtained by their study , 
there were significantly less number of patients affected by dermatitis in 
IMRT group compared to 3D CRT group. 
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         Ajay Singh Choudhary et al ( 2017)
1 
did a study  to compare the 
toxicity profile in patients with IMRT and 3D CRT modes  in a sample of 150 
patients, out of the 92 patients in the 3D CRT group, grade 3 or greater 
dermatitis occurred in 87% of the patients and out of the 58 patient in the 
IMRT group, 93.1% had grade 3 or greater dermatitis and the results of the 
study did not give statistically significant results. 
         This variation may be due to the fact that there was uneven distribution 
of study population where 3D CRT group has 92 patients and IMRT group has 
only 58 patients which might have lead to statistically insignificant results.    
COMPARISON OF XEROSTOMIA POST RT IN 3D CT Vs  IMRT 
GROUPS AND 3D CRT Vs IGRT GROUPS: 
           On comparing the xerostomia occurring  post RT between 3D CRT, 
IMRT and IGRT groups, among  the 20 patients in the 3D CRT group , 75% 
had grade 1 xerostomia , 15% had grade 2 xerostomia  and out of  the 20 
patients in the IMRT group,  65% had grade I xerostomia and 15% had grade 
2 xerostomia  and out of  the 20 patients in the IGRT group,  70% had grade 1 
xerostomia and 15% had grade 2 xerostomia. The P value is statistically  
insignificant between 3D CRT and IMRT groups ( 1.000) and statistically   
insignificant between 3D CRT and IGRT groups ( 0.532) and statistically 
insignificant between IMRT and IGRT groups ( 0.532). 
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            The results of our study are in contradiction to the results of the studies 
conducted by Bramm et al ( 2006)
8
, Tejpal Gupta et al (2012)
58
, Gupta et al  
(2012)
24
 and  Gopa Gosh et al  (2016)
20
. 
          Bramm et al (2006)
8
 conducted a study to compare the salivary flow in 
a group of 56 patients and the results showed significant difference in the 
salivary flow with 87% of  the patients affected by xerostomia  in the 3D CRT  
group and 55% of the patients affected by xerostomia in the IMRT  group with 
a P value of 0.002. 
         Tejpal Gupta et al ( 2012)
58
, compared  the toxicity profiles in 3D CRT 
and IMRT patients in a sample of  60 patients, out of the 28 patients in the 3D 
CRT group, Grade 2 xerostomia was seen in 25(89%) of the patients and out 
of the 32 patients in the IMRT group, Grade 2 xerostomia was seen in 19 
(59%) of the patients which showed statistically significant differences.  
          Gupta et al(2012)
24
   conducted a study in which  it was found that 89 
% of patients had  grade 2 or worse acute xerostomia in the 3D CRT  group  
compared to 59% in the IMRT group   and it was statistically significant with 
a P value of 0.009 
        Gopa Gosh et al (2016)
20
 had conducted a study to compare xerostomia 
in the 3D CRT and IMRT groups in a sample of 80 patients, out of the 40 in 
the 3D CRT group, grade 3 xerostomia developed in 72.5% of the patients and 
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out of the  40 patients in the IMRT group, grade 3 xerostomia developed in 
45% of the patients showing statistically significant differences.    
          The results of our study are in contradiction to the results of the study 
conducted above  as they have included patients where the planned RT has 
been given in site specific locations  sparing the parotids, but in our study all 
the cancers of the oropharyngeal regions have been included , which could 
have an effect on the parotid secretions.  
COMPARISON OF XEROSTOMIA 90 DAYS POST RT IN 3D CRT Vs 
IMRT GROUPS AND 3D CRT Vs IGRT GROUPS: 
          On comparing the xerostomia occurring  90 days   post RT between 3D 
CRT, IMRT and IGRT groups, among  the 20 patients in the 3D CRT group, 
75% had grade 1 xerostomia, 25% had grade 2 reactions  and among  the 20 
patients in the IMRT group, 85% had grade I xerostomia  and 10% had grade 
2 xerostomia  and among  the 20 patients in the IGRT group, 80% had grade 1 
xerostomia and 5% had grade 2 xerostomia. The P value is statistically highly 
significant between 3D CRT and IMRT groups ( 0.000) and statistically highly   
significant between 3D CRT and IGRT groups ( 0.000) and statistically 
insignificant between IMRT and IGRT groups ( 0.497). 
          The results of our study are in accordance with the results obtained in 
the studies of  Bramm et al ( 2006)
8
, Nutting et al ( 2011)
48
, Ajay Singh 
Choudhary et al ( 2017)
1
. 
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             Bramm et al ( 2006)
8
 have conducted a study to compare the chronic 
toxicity in xerostomia in patients undergoing  CRT (2D CRT and 3D CRT) 
and IMRT  and  found that after 6 months, the difference in the xerostomia 
levels was  81% in the CRT group and 56% in the IMRT group  with a P value 
of 0.04 which was statistically significant. 
            Nutting et al ( 2011)
48
  performed a study to compare the toxicity 
profiles   in patients undergoing 3D CRT and IMRT modes of treatment , in 
the sample size of 94 patients.  A 12 month follow-up demonstrated that grade 
2 or worse xerostomia was significantly lower in IMRT group compared to the 
3D CRT group with a statistically significant difference with a P value of < 
0.001. 
            Ajay Singh Choudhary et al ( 2017)
1
 did a study compare the toxicity 
profiles  in patients undergoing 3D CRT and IMRT modes of radiotherapy, in 
a sample of 150 patients, out of the 92  patients in the  3D CRT group, grade 2 
or greater xerostomia was seen in 58 (63%) of the patients and out of the 58 
patients in the IMRT group grade 2 or greater xerostomia developed in 12 ( 
20.7%) of the patients, which showed a statistically significant difference of   
< 0.001. 
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COMPARISON OF DYSPHAGIA POST RT IN 3D CRT Vs IMRT AND 
3D CRT Vs IGRT GROUPS: 
           On comparing the dysphagia occurring   post RT between 3D CRT, 
IMRT and IGRT groups, among  the 20 patients in the 3D CRT group, 55% 
had grade 1 dysphagia  , 35% had grade 2 dysphagia, 10% had grade 3 
dysphagia and among   the 20 patients in the IMRT group 95% had grade I 
dysphagia and 5% had grade 2 dysphagia  and among  the 20 patients in the 
IGRT group 95% had grade 1 dysphagia and 5% had grade 2 dysphagia. The P 
value is statistically highly significant between 3D CRT and IMRT groups ( 
0.000) and statistically  highly significant between 3D CRT and IGRT groups 
(0.000)  and statistically insignificant between IMRT and IGRT groups 
(0.966). 
COMPARISON OF DYSPHAGIA 90 DAYS POST RT IN 3D CRT Vs  
IMRT AND 3D CRT Vs IGRT GROUPS: 
         On comparing the dysphagia  90 days   post RT between 3D CRT, IMRT 
and IGRT groups, among  the 20 patients in the 3D CRT group,65% had grade 
1 dysphagia  , 35% had grade 2 dysphagia,  and among  the 20 patients in the 
IMRT group 50% had grade I dysphagia and 5% had grade 2 dysphagia  and 
among  the 20 patients in the IGRT group 45% had grade 1 dysphagia and 
15% had grade 2 dysphagia. The P value is statistically  significant between 
3D CRT and IMRT groups ( 0.001) and statistically highly    significant 
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between 3D CRT and IGRT groups (0.000)  and statistically insignificant 
between IMRT and IGRT groups (0.903). 
        The results of our study are in accordance with the results obtained from 
the studies of Manan Trivedi et al ( 2015)
39
,  Gopa Gosh et al  ( 2016)
20
, 
Ajay Singh Choudhary et al ( 2017)
1
. 
        Manan Trivedi  et al ( 2015)
39
  have conducted a study to compare the 
toxicity profiles in 2D CRT, 3D CRT, IMRT and IGRT modes of radiotherapy 
and it was found that in the 3
rd
 week after radiotherapy in the 2D CRT and 3D 
CRT group dysphagia was demonstrated in 33.3% and 54.5% respectively. In 
the 4
th
 week after radiotherapy, dysphagia was demonstrated in 48.78% in the 
IMRT and 47.5% in the IGRT group respectively which showed  significant 
difference between 3D CRT with IMRT  and 3D CRT with IGRT and 
insignificant differences between IMRT and IGRT. 
         Gopa Gosh  et al ( 2016 )
20
 have done a study to compare the toxicity 
profiles between patients treated in 3D CRT and IMRT modes of radiotherapy, 
in a sample of 80 patients, out of the 40 in the 3D CRT   group grade 2 
dysphagia was seen in 34 (85%) of patients  and grade 2 dysphagia was seen 
in 23 (57.5%) of patients in 3D CRT group which showed a statistically 
significant results with a P value of 0.013 
             Ajay Singh Choudhary et al ( 2017)
1
 performed a study  to compare 
the acute dysphagia in patients treated in 3D CRT and IMRT modes of 
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radiotherapy in a sample of   150 patients, out of the  92 in the 3D CRT group, 
grade 3 on greater dysphagia occurred in 84.4% of the patients and out of the 
58 patients in the IMRT group, grade 3 or greater occurred in 56.9% of the 
patients which showed a statistically significant result with a P value of < 
0.001. 
         The results of our study are in contradiction to the results of the study 
conducted by Tejpal Gupta et al ( 2012)
58
. 
         In a study conducted by Tejpal Gupta et al ( 2012)
58
 in a sample of 60 
patients in the 3D CRT and IMRT groups, out of the 28 patients in the 3D 
CRT group, grade 3  dysphagia   was demonstrated in none  of the patients and 
out of the 32 patients in the IMRT group grade 3 dysphagia was demonstrated 
in 3  (9.5%) with a P value of 0.21 which was not statistically significant. 
         Though statistically insignificant results were obtained from the study, 
the percentage of patients affected by grade 2 or greater dysphagia by 3D CRT 
is 71.5% and is  greater compared that of IMRT where the percentage of 
patients affected by grade 2 or dysphagia is 59.3% and  could be due to the 
differences in  the midline protection contouring and the location of the 
primary tumour site.  
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                    SUMMARY AND CONCLUSION 
 The present study was conducted to assess and compare the toxicity 
profiles in head and neck cancer patients undergoing 3D CRT, IMRT and 
IGRT modes of radiotherapy. 
 A total of 60 patients were included in the study which included 20 patients in 
the 3D CRT group, 20 patients in the IMRT group and 20 patients in the IGRT 
group. 
The results of the  study could be summarised as follows: 
 On comparing mucositis occurring post RT between 3D CRT and 
IMRT it was found that there was a statistically highly significant 
difference between the groups with a P value of 0.000 and  between 3D 
CRT and IGRT it was found that there was a statistically  highly 
significant difference between the groups  with a P value of 0.000. On 
comparing mucositis  occurring  90 days post RT between 3D CRT 
and IGRT it was found that there was a statistically significant 
difference of 0.010.  
 On comparing skin reactions occurring  post RT between 3D CRT and 
IMRT  it was found that there was a statistically significant difference 
between the groups with a P value of  0.004 and between  3D CRT and 
IGRT  it was found that there was a statistically significant difference 
between the groups with a  P value of  0.002 . On comparing skin 
reactions occurring 90 days post RT between 3D CRT and IMRT it 
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was found that there was a statistically highly significant difference 
between the groups with a P value of 0.000 and between 3D CRT and 
IGRT it was found that there was a statistically highly significant 
difference between the groups with a P value of 0.000. 
 On comparing xerostomia occurring 90 days  post RT between 3D 
CRT and IMRT  it was found that there was a statistically highly 
significant difference between the groups with a  P value of  0.000 and 
between 3D CRT and IGRT  it was found that there was a statistically 
highly significant difference between the groups with a  P value of  
0.000. 
 On comparing dysphagia occurring post RT between 3D CRT and 
IMRT  it was found that there was a statistically highly significant 
difference between the groups with a  P value of  0.000  and between 
3D CRT and IGRT  it was found that there was a statistically highly 
significant difference between the groups with a  P value of  0.000. On 
comparing dysphagia occurring  90 days post RT between 3D CRT and 
IMRT it was found that there was a statistically highly significant 
difference between the groups with a P value of 0.000 and  between 3D 
CRT and IGRT it was found that there was a statistically  highly 
significant difference between the groups with a P value of 0.000.In 
our study we have compared the toxicity profiles between IMRT and 
IGRT groups and have not obtained any statistically significant 
differences between the two groups. 
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           In all the studies conducted so far IMRT and IGRT have been 
considered together as a single treatment arm and it’s toxicity profiles have 
been compared with other conformal techniques. With the results obtained 
from the present study though IMRT and IGRT modes of radiotherapy are 
technically similar the difference in cost between the two modes for treatment 
delivery is huge and hence it should  be justified that IMRT is as efficoaus as 
IGRT with minimum toxicities. 
            The results of this study point to the fact that intensity of the side 
effects of radiotherapy depend not only on the dosage of the therapy but also 
on the type of radiotherapy being given to the patients. Also, it can be seen 
that onset of side effects also depends on the stage of radiotherapy. Mucositis 
is the unavoidable side effect of radiotherapy and occurs in all the patients 
undergoing any form of radiotherapy. Other acute toxic effects seen were 
dysphagia and dryness of mouth. Decreased salivation was seen as a minor 
side effect in all the therapies. Though all these side effects  were seen in all 
therapies, the onset of the effects and the percentage of patients suffering was 
different and for almost all effects, IMRT and IGRT proved to be a better 
treatment option as almost all the side effects occurred relatively later as 
compared to 3D CRT therapy and the number of patients suffering were 
smaller when compared to 3D CRT. Also, modern IMRT delivery  techniques 
do not appear to result in increased toxicities in HNSCC patients undergoing 
high dose radiation with concurrent chemotherapy. Within the limitations of 
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our study, it is suggestive of IMRT being as effective as other treatment 
strategies for locally advanced head and neck cancer and provides better 
outcomes in terms of toxicity as compared to conventional techniques. The 
small number of patients and relatively short follow up remains the major 
limitations of the present study and further studies with larger group and long 
term follow up is recommended.    
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                                    CLINICAL CHARACTERISTICS OF PATIENTS 
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CONSENT LETTER 
 
I _______________________ the undersigned hereby give my consent for the performance of 
diagnostic tests on myself for “the comparison of toxicity profiles in head and neck cancer patients 
undergoing 3D-CRT, IMRT and IGRT” being conducted by Dr. B.Niveditha under the guidance 
of Dr. S.Kailasam, Professor, Head Of the Department of Oral Medicine, Diagnosis  Radiology , 
Ragas Dental College and hospital, Chennai. I have been informed and explained about the status 
of my disease, investigation procedure, the proposed treatment procedure, risk involved and 
likelihood of success. I also understand and accept that as a part of this study protocol, thereby 
voluntarily, unconditionally, freely give my consent without any fear or pressure in mentally 
sound and conscious state to participate in the study. 
 
Witness/Representative:       Patient’s Signature 
          Date:  
 
     ஒப்புதல் கடிதம் 
 
 ஥ான்_____________________ என்னுடைன முழு ஒத்துடமப்ட஧ திருநதி.        
அயர்கள் நற்றும், திரு.S. டக஬ாசம் தட஬டந ப஧பாசிரினர், யாய் நருத்துயம் 
நற்றும் யாய்ப஥ாய் அ஫ிதல் கதிர் யசீ்சுத்துட஫ பாகாஸ் ஧ல் நருத்துய முது஥ிட஬ 
஧டிப்஧ிற்கா஦ என்னுடைன                                   
          ஧ரிபசாதட஦கள் சசய்ன ஥ான் என் முழு சுன஥ிட஦யில் 
னாருடைன யற்புறுத்தல் இல்஬ாநல், னாருடைன கட்டுப்஧ாட்டிற்க்கு கீழ்஧ணினாநலும் 
என்னுடைன முழு ஒத்துடமப்ட஧யும் இந்த நருத்துய ஆபாய்ச்சிக்காக ஒப்புதட஬ 
அ஭ிக்கின்ப஫ன். 
சாட்சிகள்:         டகசனாப்஧ம் 
பததி :  
    
      
Appendix L 
 
Copyright © 2009 National Marrow Donor Program ® and The Medical College of Wisconsin 
 
Document Title: Forms Manual: Appendix L- Karnofsky/Lansky Performance Status                                                                                 
Document Number: A00428 revision 1 
Page 1 of 5 
 
Karnofsky/Lansky Performance Status  
 
The CIBMTR uses Karnofsky/Lansky performance status to determine the 
functional status of a recipient. Recipient performance status is a critical data 
field that has been determined to be essential for all outcome-based analyses. 
The Karnofsky Scale is designed for recipients aged 16 years and older, and the 
Lansky Scale is designed for recipients less than 16 years old. Use this scale 
(see table 1) to determine the score (10-100) that best represents the recipient’s 
activity status at the requested time point.  
 
Table 1. Karnofsky/Lansky Scale 
Karnofsky Scale (recipient age ≥ 16 years) Lansky Scale (recipient age <16 years) 
Able to carry on normal activity; no special care 
is needed 
Able to carry on normal activity; no special care 
is needed 
100 Normal,  no complaints,  no evidence of disease 100 Fully active 
90 Able to carry on normal activity 90 Minor restriction in physically strenuous play 
80 Normal activity with effort 80 Restricted in strenuous play, tires more easily, otherwise active 
Unable to work,  able to live at home cares for 
most personal needs,  a varying amount of 
assistance is needed 
Mild to moderate restriction 
70 Cares for self,  unable to carry on normal activity or to do active work 70 
Both greater restrictions of, and less time 
spent in active play 
60 Requires occasional assistance but is able to care for most needs 60 
Ambulatory up to 50% of time, limited active 
play with assistance/supervision 
50 Requires considerable assistance and frequent medical care 50 
Considerable assistance required for any 
active play,  fully able to engage in quiet 
play 
Unable to care for self,  requires equivalent of 
institutional or hospital care,  disease may be 
progressing rapidly 
Moderate to severe restriction 
40 Disabled,  requires special care and assistance 40 Able to initiate quite activities  
30 Severely disabled,  hospitalization indicated, although death not imminent 30 
Needs considerable assistance for quiet 
activity 
20 Very sick,  hospitalization necessary 20 Limited to very passive activity initiated by others (e.g., TV) 
10 Moribund,  fatal process progressing rapidly 10 Completely disabled, not even passive play 
 
Karnofsky/Lansky Performance Score vs. ECOG performance score: 
Some transplant centers may prefer to collect and use the ECOG performance 
score as opposed to the Karnofsky/Lansky score. Although the ECOG and 
Karnofsky/Lansky performance score systems are based on similar principles, 
the scales are not the same. For centers that collect only the ECOG 
performance score, see the memorandum and worksheet example on the 
following pages. 
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MEMORANDUM 
 
To:  Transplant center primary contacts 
 
From:  Debra Christianson and Douglas Rizzo, MD MS 
 
RE: Provision of Karnofsky performance score (KPS) versus ECOG 
performance score (ECOG PS) to CIBMTR. 
 
Date: January 31, 2009 
 
 
CIBMTR has collected the Karnofsky performance score for adult transplant 
recipients at the time of HCT and during the follow-up period for over two 
decades. This score, reported on an ordinal scale from 0 to 100, provides a 
rough measure of the patient’s well-being, including their ability to conduct 
activities of daily living and functional capacity. In children, the Lansky score 
serves a similar purpose. 
 
As a data item, the pre-HCT KPS is included in virtually all analyses performed 
by the CIBMTR as an adjustment factor for outcomes of HCT. It is a statistically 
significant pre-HCT patient risk factor in nearly every analysis of outcomes, 
including the unrelated Center Specific Outcomes reports created by the NMDP.  
Therefore, CIBMTR believes that accurate collection and reporting of the 
performance score is very important, and should be included in the routine 
auditing of data at transplant centers. 
 
Methods to accurately collect and report performance scores vary across 
transplant programs. In general, it appears best if the performance score is 
reported in a systematic fashion at the time of assessment by a clinician in a way 
that is readily available to the data professionals that report the data to CIBMTR. 
Although the KPS is very commonly used, some institutions have a preference to 
collect and use the ECOG PS at their center. This may occur because of heavy 
involvement in ECOG clinical studies, or other institutional preference. Centers 
using primarily ECOG PS have asked whether they can report ECOG PS to 
the CIBMTR, and how to account for differences between ECOG PS and 
KPS when reporting. 
 
Although ECOG PS and KPS rest on similar foundations to record performance 
status, their scales are not alike. KPS is more detailed and is described in 11 
categories, whereas the ECOG PS is reported in six categories. Conversion 
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instruments between ECOG PS (Zubrod-WHO) and KPS exist and have been 
validated. However, unfortunately, because of differences in the number of 
categories, there exists an overlap between the categories of functionality 
included in the two systems. For example, ECOG PS 1 can be mapped to either 
KPS categories 80 or 90. This lack of 1:1 mapping in the direction of ECOG PS 
to KPS causes an inherent problem for centers collecting ECOG PS and wishing 
to report KPS to CIBMTR or other entities. 
 
Because of the greater detail found in the KPS, as well as its reproducible effect 
in HCT outcomes analyses over the past two decades, CIBMTR plans to 
continue to collect performance scores using the KPS system, and will also audit 
source records at transplant centers based upon the KPS system. Since there 
exists a 1:1 directional mapping of KPS to ECOG PS, we believe some centers 
that must report ECOG PS to other entities may be accommodated by collecting 
the KPS primarily, and converting to ECOG PS for those entities that request an 
ECOG PS. However, for those centers wishing to collect only the ECOG PS, 
CIBMTR will make the following accommodations when auditing the source 
data regarding KPS as reported to CIBMTR: 
 
• Centers collecting ECOG PS should do so using standard practices to 
assure its accuracy. 
 
• Conversion of ECOG PS to KPS for the purposes of CIBMTR reporting 
should follow a standard and reproducible practice to account for the lack 
of direct 1:1 mapping from ECOG to KPS. This practice should be 
transparent and reproducible such that an auditor reviewing patient 
records and center conversion tools can readily reproduce the derived 
KPS across the full spectrum of patients included in an audit. Although 
CIBMTR cannot pre-determine whether any particular practice is 
sufficient, and example “process” might include: 
o A physician records the patient’s ECOG PS at the time of an office 
visit, along with their actual performance capabilities that would 
determine the score. 
o The data professional reporting to the CIBMTR takes the recorded 
ECOG PS, and reads the applicable recorded history about the 
patient’s functional capacity. 
o Using a standardized worksheet (see attached example), the data 
professional maps the recorded ECOG PS to a KPS for reporting to 
the CIBMTR. Such a worksheet may include space for text to 
record specific statements in the medical record that substantiate 
the chosen conversion, as well as check boxes to acknowledge the 
original document where the functional status statements 
originated. The worksheet might also include both scoring systems, 
to facilitate conversion. 
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o The worksheet is signed and dated, then placed in the patient’s 
medical chart and available for future auditing purposes. 
 
As audits reveal “best practices” for those centers where only the ECOG PS is 
collected, CIBMTR will provide additional suggestions to other centers that may 
follow this practice at the time of auditing. 
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Conversion Worksheet: ECOG to Karnofsky/Lansky 
 
Patient Name/ID#:___________________________ 
Date/Follow-up period:            
 Pre-transplant    6 months     Chronic GVHD 
 100 days    Annual, specify year:    Other, specify:       
     
Supporting documentation from medical record: 
PERFORMANCE STATUS CRITERIA 
ECOG (Zubrod) Karnofsky Lansky 
Score Description Score Description Score Description 
100 Normal, no complaints, no evidence of disease. 100 Fully active, normal. 
0 
Fully active, able to carry 
on all pre-disease 
performance without 
restriction. 90 
Able to carry on normal activity, 
minor signs or symptoms of 
disease. 
90 Minor restrictions in physically strenuous activity. 
80 Normal activity with effort, some signs or symptoms of disease. 80 Active, but tires more quickly. 
1 
Restricted in physically 
strenuous activity but 
ambulatory and able to 
carry out work of a light 
or sedentary nature, e.g., 
light housework, office 
work. 
70 Cares for self, unable to carry on normal activity or do active work. 70 
Both greater restriction of, and 
less time spent in, play activity. 
60 
Requires occasional assistance, 
but is able to care for most of 
his/her needs. 
60 
Up and around, but minimal 
active play; keeps busy with 
quieter activities. 
2 
Ambulatory and capable 
of all selfcare but unable 
to carry out any work 
activities.  Up and about 
more than 50% of 
waking hours. 
50 
Requires considerable 
assistance and frequent medical 
care. 
50 
Gets dressed, but lies around 
much of the day; no active play; 
able to participate in all quiet play 
and activities. 
40 Disabled, requires special care and assistance. 40 
Mostly in bed, participates in 
quiet activities. 
3 
Capable of only limited 
selfcare, confined to bed 
or chair more than 50% 
of waking hours. 30 
Severely disabled, hospitalization 
indicated. Death not imminent. 30 
In bed, needs assistance even 
for quiet play. 
20 Very sick, hospitalization indicated. Death not imminent. 20 
Often sleeping, play entirely 
limited to very passive activities. 
4 
Completely disabled. 
Cannot carry on any 
selfcare. Totally confined 
to a bed or chair. 10 
Moribund, fatal processes 
progressing rapidly. 10 No play, does not get out of bed. 
5 Dead 0 Dead 0 Dead 
 
 
 
Reported ECOG: ______________   Converted KPS: _____________  
 
M.D. Signature: _________________________________________________________ 
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Radiation Oncology/Toxicity grading/RTOG
Front Page: Radiation Oncology | RTOG Trials | Randomized
Trials
RTOG/EORTC Radiation Toxicity Grading
RTOG Common Toxicity Criteria
1995 - PMID 7713792 — "Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European
Organization for Research and Treatment of Cancer (EORTC)." Cox JD et al. Int J Radiat Oncol Biol Phys. 1995 Mar
30;31(5):1341-6.
For all: 0 - no symptoms, 5 - death directly related to radiation effects
ACUTE
RTOG ACUTE Radiation Morbidity
Tissue Grade 1 2 3 4
Skin
Follicular, faint or dull erythema /
epilation / dry desquamation /
decreased sweating
Tender or bright erythema,
patchy moist desquamation /
moderate edema
Confluent, moist desquamation
other than skin folds, pitting
edema
Ulceration,
hemorrhage,
necrosis
Mucous
membrane
Irritation / may experience mild
pain not requiring analgesic
Patchy mucositis that may
produce an inflammatory
serosanguinous discharge / may
experience moderate pain
requiring analgesia
Confluent fibrinous mucositis /
may include severe pain
requiring narcotic
Ulceration,
hemorrhage or
necrosis
Eye
Mild conjunctivitis w/ or w/o
scleral injection / increased
tearing
Moderate conjunctivitis w/ or w/o
keratitis requiring steroids and/or
antibiotics / dry eye requiring
artificial tears / iritis with
photophobia
Severe keratitis with corneal
ulceration / objective decrease in
visual acuity or in visual fields /
acute glaucoma /
panophthalmitis
Loss of vision
(uni or
bilateral)
Ear
Mild external otitis with
erythema, pruritus, secondary to
dry desquamation not requiring
medication. Audiogram
unchanged from baseline
Moderate external otitis requiring
topical medication / serous otitis
media / hypoacusis on testing
only
Severe external otitis with
discharge or moist
desquamation / symptomatic
hypoacusis / tinnitus, not drug
related
Deafness
Salivary
gland
Mild mouth dryness / slightly
thickened saliva / may have
slightly altered taste such as
metallic taste / these changes
not reflected
in alteration in baseline
feeding behavior, such as
increased use of liquids
with meals
Moderate to complete dryness /
thick, sticky saliva / markedly
altered taste
(none) Acute salivarygland necrosis
Pharynx &
esophagus
Mild dysphagia or odynophagia /
may require topical anesthetic or
non-narcotic analgesics / may
require soft diet
Moderate dysphagia or
odynophagia / may require
narcotic analgesics / may require
puree or liquid diet
Severe dysphagia or
odynophagia with dehydration or
weight loss > 15% from
pretreatment baseline requiring
NG feeding tube, IV fluids, or
hyperalimentation
Complete
obstruction,
ulceration,
perforation,
fistula
Larynx
Mild or intermittent hoarseness /
cough not requiring antitussive /
erythema of mucosa
Persistent hoarseness but able
to vocalize / referred ear pain,
sore throat, patchy fibrinous
exudate or mild arytenoid edema
not requiring narcotic / cough
requiring antitussive
Whispered speech, throat pain
or referred ear pain requiring
narcotic / confluent fibrinous
exudate, marked arytenoid
edema
Marked
dyspnea,
stridor or
hemoptysis
with
tracheostomy
or intubation
necessary
Upper GI
Anorexia with ≤ 5% weight loss
from pretreatment baseline /
nausea not requiring antiemetics
/ abdominal discomfort not
requiring parasympatholytic
drugs or analgesics
Anorexia with ≤ 15% weight loss
from pretreatment baseline /
nausea and/or vomiting requiring
antiemetics / abdominal pain
requiring analgesics
Anorexia with > 15% weight loss
from pretreatment baseline or
requiring NG tube or parenteral
support. Nausea and/or vomiting
requiring tube or parenteral
support / abdominal pain, severe
despite medication /
hematemesis or melena /
abdominal distention (flat plate
radiograph demonstrates
distended bowel loops)
Ileus, subacute
or acute
obstruction,
perforation, GI
bleeding
requiring
transfusion /
abdominal pain
requiring tube
decompression
or bowel
diversion
Lower GI /
Pelvis
Increased frequency or change
in quality of bowel habits not
requiring medication / rectal
discomfort not requiring
analgesics
Diarrhea requiring
parasympatholytic drugs (e.g.
Lomotil) / mucous discharge not
necessitating sanitary pads /
rectal or abdominal pain
requiring analgesics
Diarrhea requiring parenteral
support / severe mucous or
blood discharge necessitating
sanitary pads / abdominal
distention (flat plate radiograph
demonstrates distended bowel
loops)
Acute or
subacute
obstruction,
fistula or
perforation; GI
bleeding
requiring
transfusion;
abdominal pain
or tenesmus
requiring tube
decompression
or bowel
diversion
Lung Mild symptoms of dry cough ordyspnea on exertion
Persistent cough requiring
narcotic, antitussive agents /
dyspnea with minimal efort but
not at rest
Severe cough unresponsive to
narcotic antitussive agent or
dyspnea at rest / clinical or
radiological evidence of acute
Severe
respiratory
insufficiency /
continuous
oxygen or
pneumonitis / intermittent
oxygen or
steroids may be required
assisted
ventilation
Genitourinary
Frequency of urination or
nocturia twice pretreatment habit
/ dysuria, urgency not requiring
medication
Frequency of urination or
nocturia that is less frequent
than every hour. Dysuria,
urgency, bladder spasm
requiring local anesthetic (e.g.
Pyridium)
Frequency with urgency and
nocturia hourly or more
frequenty / dysuria, pelvis pain
or bladder spasm requiring
regular, frequent narcotic / gross
hematuria
with/without clot passage
Hematuria
requiring
transfusion /
acute bladder
obstruction not
secondary to
clot passage,
ulceration, or
necrosis
Heart
Asymptomatic but objective
evidence of EKG changes or
pericardial abnormalities without
evidence of other heart disease
Symptomatic with EKG changes
and radiological findings of
congestive heart failure or
pericardial disease / no specific
treatment required
Congestive heart failure, angina
pectoris, pericardial disease
responding to therapy
Congestive
heart failure,
angina
pectoris,
pericardial
disease,
arrhythmias not
responsive to
nonsurgical
measures
CNS
Fully functional status (i.e. able
to work) with minor neurological
findings, no medication needed
Neurological findings present
sufficient to require home care /
nursing assistance may be
required / medications including
steroids/antiseizure agents may
be required
Neurological findings requiring
hospitalization for initial
management
Serious
neurological
impairment that
includes
paralysis,
coma, or
seizures > 3
per week
despite
medication /
hospitalization
required
HEME 1 2 3 4
WBC 3.0 - < 4.0 2.0 - < 3.0 1.0 - < 2.0 < 1.0
Platelets 75 - < 100 50 - < 75 25 - < 50
<25 or
spontaneous
bleeding
Neutrophils 1.5 - < 1.9 1.0 - < 1.5 0.5 - < 1.0 < 0.5 or sepsis
Hgb / Hct 11 - 9.5 (28% - < 32%) < 9.5 - 7.5 ( < 28%) < 7.5 - 5.0 (Packed celltransfusion required) (none)
For all: 0 - no symptoms, 5 - death directly related to radiation effects
LATE
RTOG/EORTC LATE Radiation Morbidity
Tissue Grade 1 2 3 4
Skin
Slight atrophy;
pigmentation change;
some hair loss
Patch atrophy; moderate
telangiectasia; total hair
loss
Marked atrophy; gross
telangiectasia Ulceration
Subcutaneous
tissue
Slight induration (fibrosis)
and loss of subcutaneous
fat
Moderate fibrosis but
asymptomatic; slight field
contracture; <10% linear
reduction
Severe induration and
loss of subcutaneous
tissue; field contracture >
10% linear measurement
Necrosis
Mucous
membrane
Slight atrophy and
dryness
Moderate atrophy and
telangiectasia; little
mucous
Marked atrophy with
complete dryness Ulceration
Salivary glands
Slight dryness of mouth;
good response on
stimulation
Moderate dryness of
mouth; poor response on
stimulation
Complete dryness of
mouth; no response on
stimulation
Fibrosis
Spinal cord Mild L'Hermitte'ssyndrome
Severe L'Hermitte's
syndrome
Objective neurological
findings at or below cord
level treated
Mono, para quadraplegia
Brain Mild headache; slightlethargy
Moderate headache;
great lethargy
Severe headache; severe
CNS dysfunction (partial
loss of power or
dyskinesia)
Coma
Eye
Asymptomatic cataract;
minor corneal ulceration
or keratitis
Symptomatic cataract;
moderate corneal
ulceration; minor
retinopathy or glaucoma
Severe keratitis; severe
retinopathy or detachment
Panophthalmitis /
blindness
Larynx Hoarseness; slightarytenoid edema
Moderate arytenoid
edema; chondritis
Severe edema; severe
chondritis Necrosis
Lung
Asymptomatic or mild
symptoms (dry cough);
slight radiographic
appearances
Moderate symptomatic
fibrosis or pneumonitis
(severe cough); low grade
fever; patchy radiographic
appearances
Severe symptomatic
fibrosis or pneumonitis;
dense radiographic
changes
Severe respiratory
insufficiency / Continuous
oxygen / assisted
ventilation
Heart
Asymptomatic or mild
symptoms; transient T
wave inversion & ST
changes; sinus tachy >
110 (at rest)
Moderate angina on
effort; mild pericarditis;
normal heart size;
persistent abnormal T
wave and ST changes;
low ORS
Severe angina; pericardial
effusion; constrictive
pericarditis; moderate
heart failure; cardiac
enlargement; EKG
abnormalities
Tamponade / severe heart
failure; severe constrictive
pericarditis
Esophagus
Mild fibrosis; slight
difficulty in swallowing
solids; no pain on
swallowing
Unable to take solid food
normally; swallowing
semisolid food; dilatation
may be indicated
Severe fibrosis; able to
swallow only liquids; may
have pain on swallowing;
dilatation required
Necrosis / perforation
fistula
Small/Large
intestine
Mild diarrhea; mild
cramping; bowel
movement 5 times daily;
slight rectal discharge or
bleeding
Moderate diarrhea and
colic; bowel movement >
5 times daily; excessive
rectal mucus or
intermittent bleeding
Obstruction or bleeding,
requiring surgery
Necrosis / perforation
fistula
Liver
Mild lassitude; nausea,
dyspepsia; slightly
abnormal liver function
Moderate symptoms;
some abnormal liver
function tests; serum
albumin normal
Disabling hepatic
insufficiency; liver function
tests grossly abnormal;
low albumin; edema or
ascites
Necrosis / hepatic coma
or encephalopathy
Kidney
Transient albuminuria; no
hypertension; mild
impairment of renal
function; urea 25-35
mg/dL; creatinine 1.5-2.0
mg/dL; creatinine
clearance > 75%
Persistent moderate
albuminuria (2+); mild
hypertension; no related
anemia; moderate
impairment of renal
function; urea > 36-60;
creatinine clearance 50-
74%
Severe albuminuria;
severe hypertension;
persistent anemia (< 10);
severe renal failure; urea
> 60; creatinine > 4.0;
creatinine clearance <
50%
Malignant hypertension;
uremic coma; urea > 100
Bladder
Slight epithelial atrophy;
minor telangiectasia
(microscopic hematuria)
Moderate frequency;
generalized
telangiectasia; intermittent
macroscopic hematuria
Severe frequency &
dysuria; severe
telangiectasia (often with
petechiae); frequent
hematuria; reduction in
bladder capacity (<150
cc)
Necrosis/contracted
bladder (capacity < 100
cc); severe hemorrhagic
cystitis
Bone
Asymptomatic; no growth
retardation; reduced bone
density
Moderate pain or
tenderness; growth
retardation; irregular bone
sclerosis
Severe pain or
tenderness; complete
arrest of bone growth;
dense bone sclerosis
Necrosis / spontaneous
fracture
Joint Mild joint stiffness; slightlimitation of movement
Moderate stiffness;
intermittent or moderate
Severe joint stiffness;
pain with severe limitation
Necrosis / complete
fixation
joint pain; moderate
limitation of movement
of movement
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